Patent Grant
10815290
Single chain, multimerized, and/or glycosylated NKG2D decoys are described. The NKG2D decoys have high affinity and avidity for surface bound and soluble NKG2D ligands and can be used to (i) identify NKG2D ligands; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses.
NKG2D is a receptor found on the surface of many immune system cells, such as essentially all natural killer cells and CD8 T cells, subsets of CD4 T cells, and most gamma delta T cells. Ligand binding to the NKG2D receptor results in immune cell stimulation. While NKG2D-based stimulation of immune cells can be beneficial, it is also associated with numerous pathological conditions such as a number of inflammatory conditions. Moreover, activation of the immune system through NKG2D binding can dampen the effectiveness of vaccine administrations.
There are multiple molecules that serve as stimulating ligands for the NKG2D receptor. Most of these NKG2D ligands (NKG2DL) are not expressed or are expressed at low levels in normal cells. However, the expression of NKG2DL is upregulated in various pathological conditions. As one example, certain types of cancer cells express NKG2DL. Expression of NKG2DL also occurs in intestinal epithelial cells and under conditions of stress or infection.
Earlier studies targeted the NKG2D pathway as a potential cancer immunotherapy. These studies focused on monoclonal antibodies made against one particular NKG2DL, MICA. This work is described in, for example, WO 2008/036981. Briefly, it was observed that induction of high-titer antibodies against MICA in cancer patients elicited an anti-tumor response. As stated, however, there are numerous NKG2DL beyond MICA. Human ligands for NKG2D include MICA, MICB, and the RAET1/ULBP family (e.g., RAET1E/ULBP4, RAET1G/ULBP5, RAET1H/ULBP2, RAET1/ULBP1, RAET1L/ULBP6, and RAET1N/ULBP3).
Recognizing that it would be beneficial to target more than one NKG2DL, WO2010/080124 describes construction of a chimeric molecule comprising one NKG2D monomer (i.e., one half of a functional NKG2D homodimer binding domain) and an Fc portion for the treatment of cancer. WO2010/080124 explains that this NKG2D-Fc chimera can target any or all NKG2DL that are expressed on human tumor cells, and that they are thus capable of mediating tumor cell destruction through complement lysis and antibody-dependent cell-mediated cytotoxicity (ADCC). The described NKG2D-Fc chimera promotes efficient cross-presentation (e.g., priming) by dendritic cells, leading to the induction of potent T cell responses against the tumor. Moreover, WO2010/080124 states that this chimera is capable of binding and sequestering any “shed” (e.g., soluble or released) NKG2DL produced by tumor cells.
While WO2010/080124 describes an interesting chimeric construct to more broadly neutralize a number of NKG2D ligands (NKG2DL), whether expressed on a tumor cell surface or shed, aspects of the chimeric construct detract from its ability to strongly bind and suppress the actions of NKG2DL. This is because, in part, NKG2D only binds its ligands with moderate affinities. Moreover, NKG2D must form a homodimer to effectively bind its ligands. Thus, at least two monomeric chimeric constructs of WO2010/080124 must be present to effectively bind a NKG2DL. While a sufficient number of chimeric constructs could potentially be administered at a local tumor site, the dosing required to achieve binding of shed ligands within the circulation (e.g., disseminated tumor cells, blood cancer cells) could be prohibitively high.
The present disclosure describes NKG2D decoys that include at least two NKG2D monomers within a construct so that each construct includes at least one functioning NKG2D homodimer. Thus, one construct can effectively bind and neutralize a NKG2DL whether cell bound or shed, even in the circulation. The NKG2D decoys can also have additional beneficial attributes that further enhance NKG2DL binding and sequestration. These further attributes include one or more of: expression as a single chain construct; multimerization to form avid decoys that tightly, and more competitively, bind NKG2DL; and/or glycosylation. Glycosylation can contribute to proper protein folding and facilitate protein-protein interactions.
The described NKG2D decoys can be used to (i) identify unknown or locate NKG2DL; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine, as well as many other potential uses.
Many of the drawings submitted herein are better understood in color, which is not available in patent application publications at the time of filing. Applicant considers the color versions of the drawings as part of the original submission and reserves the right to present color images of the drawings in later proceedings.
NKG2D is an activating receptor found on the surface of many immune system cells, such as essentially all natural killer cells and CD8 T cells, subsets of CD4 T cells, and most gamma delta T cells. More particularly, NKG2D is a type II transmembrane glycoprotein having an extracellular lectin-like domain. This domain lacks the recognizable calcium-binding sites found in true C-type lectins and binds protein rather than carbohydrate ligands. NKG2D has also been referred to as KLRKI; killer cell lectin-like receptor subfamily K, member 1; CD314; KLR; NKG2-D; FLJ17759; FLJ75772 and D12S2489E.
NKG2D exists as a disulfide-linked homodimer that delivers an activating signal upon ligand binding. Signaling requires association with an adapter protein. Alternative splicing of NKG2D mRNA results in isoforms with different cytoplasmic domains that can associate either with DAP12 to deliver a true activating signal or with DAP10 resulting in a costimulatory signal. NKG2D has been implicated in immune surveillance and the immune response against viral infection. In addition, elevated levels of NKG2D ligands (NKG2DL) have been detected in proliferating cells and many types of cancer. Based on these observations, it has been suggested that expression levels of NKG2DL, MICA in particular, may provide useful information for the detection and/or diagnosis of cancer.
To that end, earlier studies targeting the NKG2D pathway with respect to potential cancer immunotherapy focused on monoclonal antibodies made against the NKG2DL, MICA. This work is described in WO 2008/036981, entitled “Methods for treating MICA-related disorders.” Briefly, it was observed that induction of high-titer antibodies against MICA in cancer patients elicited an anti-tumor response.
There are numerous NKG2DL beyond MICA, however. Human ligands for NKG2D include the MIC family (MICA and MICB) and the RAET1/ULBP family. Members of the RAET1/ULBP family include: RAET1E/ULBP4, RAET1G/ULBP5, RAET1H/ULBP2, RAET1/ULBP1, RAET1L/ULBP6, and RAET1N/ULBP3. Mouse ligands for NKG2D include minor histocompatibility antigen 60 (H60) and retinoic acid early inducible transcript (RAE-I).
Recognizing the benefit of binding numerous NKG2DL, WO2010/080124 describes construction of a chimeric molecule including one NKG2D monomer (one half of an NKG2D homodimer binding domain) and an Fc portion for the treatment of cancer. WO2010/080124 explains that the NKG2D-Fc chimera can target any or all NKG2DL that are expressed on human tumor cells, and that they are thus capable of mediating tumor cell destruction through complement lysis and antibody-dependent cell-mediated cytotoxicity (ADCC). The described monomeric NKG2D-Fc chimera promotes efficient cross-presentation (e.g., priming) by dendritic cells, leading to the induction of potent T cell responses against the tumor. Moreover, WO2010/080124 states that this chimera is capable of binding and sequestering any “shed” (e.g., soluble or released) NKG2DL produced by tumor cells.
While WO2010/080124 describes an interesting chimeric construct to more broadly neutralize a number of NKG2DL, whether expressed on a tumor cell surface or shed, aspects of the chimeric construct, detract from its ability to strongly bind and suppress the actions of NKG2DL. This is because, in part, NKG2D only binds its ligands with moderate affinities. Moreover, NKG2D must form a homodimer to effectively bind its ligands. Thus, at least two chimeric constructs of WO2010/080124 must be present to effectively bind and sequester a NKG2DL. While a sufficient number of constructs could potentially be administered at a local tumor site, the dosing required to achieve binding of shed ligands within the circulation (e.g., disseminated tumor cells, blood cancer cells) could be prohibitively high.
The present disclosure describes NKG2D decoys that include at least two NKG2D monomers within a construct such that each construct includes a functioning NKG2D homodimer. Thus, one construct can effectively bind and neutralize a NKG2DL whether cell bound or shed, even into the circulation. The NKG2D decoys can also have beneficial attributes that further enhance NKG2DL binding and sequestration. These further attributes include one or more of: expression as a single chain construct; multimerization to form avid decoys that tightly, and more competitively, bind NKG2DL; and/or glycosylation. Glycosylation can contribute to proper protein folding and facilitate protein-protein interactions.
As indicated, in particular embodiments, the NKG2D decoys have high affinity and avidity. High affinity means a dissociation constant, KD, of 10−8 M or less, in particular embodiments from 10−8 M to 10−14 M, or in particular embodiments from 10−9 M to 10−12 M. In particular embodiments, high avidity means that a NKG2D decoy binds at least 2 NKG2DL, at least 3 NKG2DL, at least 4 NKG2DL, at least 5 NKG2DL, at least 6 NKG2DL, or at least 7 NKG2DL, at an overlapping time with high affinity. The NKG2DL bound at overlapping times can be the same NKG2DL or can be different NKG2DL.
In particular embodiments, the NKG2D decoys reduce or eliminate NKG2D access to NKG2DL in a physiologically relevant manner. In particular embodiments, such reductions can be demonstrated through in vitro assays wherein native NKG2D signaling is statistically significantly reduced or even prevented. One exemplary in vitro assay is an in vitro NK cell activation assay. Reductions or elimination can also be demonstrated through effective clinical treatments as described in detail elsewhere herein.
Aspects of the current disclosure are now described in more detail.
NKG2D Monomers. NKG2D decoys disclosed herein include at least two NKG2D monomers. The full length sequence of NKG2D has been described in the literature. See, for example, Accession: NP_031386 (SEQ ID NO: 76). Additionally, alternative splice variants of NKG2D have been described. Further relevant NKG2D sequences may be identified by searching databases of DNA or protein sequences, using commonly available search programs such as BLAST. Any NKG2D sequence or splice variant may be used so long as when constructed, the NKG2D decoy binds at least one NKG2DL with high affinity.
NKG2D monomers of the NKG2D decoys may also include partial sequences (i.e., a fragment) of the NKG2D receptor polypeptide, provided that the resulting polypeptide, when constructed as a NKG2D decoy, retains the ability to bind at least one NKG2DL with high affinity. For example, NKG2D monomers of the NKG2D decoys can be shortened at either end of the NKG2D sequence by one or more amino acid residues. More specifically, the N-terminus of the NKG2D sequence can be truncated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80 or more residues, including all integers in between 1-80. Similarly, the C-terminus of the NKG2D sequence can be truncated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80 or more residues, including all integers in between 1-80. In particular embodiments, both the N-terminus and the C-terminus may be truncated.
In particular embodiments, all or part of the intracellular portion of NKG2D can be deleted. For example, the NKG2D monomers can include predominantly or completely the extracellular fragment of the NKG2D receptor. Structural analyses have revealed that amino acid residues 78 to 216 (or 150-207) of the human NKG2D sequence correspond to the extracellular portion of the NKG2D, containing ligand-binding sites. For a murine counterpart, the extracellular domain is amino acid residues 78-232, 94-232, 92-232, or 166-223. Accordingly, in particular embodiments, the NKG2D monomers include the corresponding portion of the NKG2D sequence, e.g., amino acid residues 78-216 (or 150-207) of human NKG2D; and/or 78-232, 94-232, 92-232, and/or 166-223 of murine NKG2D.
In particular embodiments, NKG2D monomers can include one or more mutations, for example, at the interface of NKG2D-ligand binding. For comprehensive information regarding the amino acid residues that are involved in receptor-ligand contact, see, for example, Strong & McFarland, 2004, Advances in Protein Chemistry, 68: 281-213; Li et al., May 2001, Nature Immunology, 2(5): 443-451; McFarland & Strong, December 2003, Immunity, 19: 803-812; and MacFarland et al., April 2003, Structure, 11: 411-422. For additional information regarding NKG2D binding to MICA particularly, see, for example, Lengyel et al., 2007, J. Biol. Chem., 282: 30658-666. As particular examples, residues of human NKG2D important for binding to MICA include Y152, Q185, K197, Y199, E201 and N207. Residues of human NKG2D important for binding to ULBP3 include Y199 and Y152. Residues of murine NKG2D important for binding to RAE-13 include K166, Y168, Y215, K213, E217 and N223. In particular embodiments, therefore, most or all of these residues can be maintained without a mutation or deletion at the position where broad permissibility (e.g., specificity) for multiple NKG2DL is desirable. However, it is also possible to design NKG2D monomers that preferentially bind one ligand over another ligand by strategically introducing a mutation at one or more of these key residues that confer selective ligand-recognition and binding. On the other hand, certain amino acid residues are involved in the binding of various ligands. For example, Y152 and Y199 in human NKG2D, which are equivalent to Y168 and Y215 respectively in the murine counterpart, contribute to the binding of MICA as well as ULBP3. Therefore, in particular embodiments, these residues are unmodified so as to retain broad ligand specificity.
Based on these resources, among others, one of ordinary skill in the art can determine the amino acid residues of NKG2D that contribute to the interaction with a ligand and test the effect of mutations by systematically altering the key residues. In any of the embodiments, the resulting NKG2D monomers are capable of binding an NKG2DL with high affinity when in homodimeric form within a decoy disclosed herein.
Exemplary methods for assaying homodimer/NKG2DL binding include ELISA, surface plasmon resonance analysis, CD analysis, fluorescence quenching, size-exclusion binding assay and isothermal titration calorimetry. For brief descriptions of these assays, see, for example, Lengyel et al. (2007).
Particular embodiments can utilize an exemplary human NKG2D: MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPWKSKCRENASPFFFC CFIAVAMGIRFIIMVAIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDE SKNVVYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHVVMGLVHIPTNGSWQWEDGS ILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV (SEQ ID NO: 1) as a NKG2D monomer or an extracellular fragment thereof. Additional examples of human NKG2D monomers include SEQ ID NO: 76 (
Particular examples of human NKG2D monomers also include:
Particular embodiments can utilize an exemplary murine NKG2D: MSKCHNYDLKPAKWDTSQEQQKQRLALTTSQPGENGIIRGRYPIEKLKISPMFVVRVLAIALAIR FTLNTLMWLAIFKETFQPVLCNKEVPVSSREGYCGPCPNNWICHRNNCYQFFNEEKTWNQSQ ASCLSQNSSLLKIYSKEEQDFLKLVKSYHWMGLVQIPANGSWQWEDGSSLSYNQLTLVEIPKG SCAVYGSSFKAYTEDCANLNTYICMKRAV (SEQ ID NO: 2) or an extracellular fragment thereof as a NKG2D monomer.
Particular examples of murine NKG2D monomers also include:
Single Chains. Particular embodiments of NKG2D decoys use a single-chain including two NKG2D monomers that form a functioning NKG2D homodimer (NKG2Dscd). Expression of a NKG2Dscd decoy can increase the efficiency of protein production and/or can enhance physiologic activity. Protein production efficiency can be improved by expressing the decoy as a NKG2Dscd because protein folding is stabilized by intramolecular interactions, and therefore the intramolecular interactions between the two NKG2D monomers (particularly the disulfide bonds promote folding). Furthermore, the physiologic activity of the NKG2D decoys can be enhanced through use of a NKG2Dscd because the NKG2D monomers are in the constitutively active (dimer binding domain) form. The NKG2Dscd form also dramatically simplifies using the active, homodimeric NKG2D binding domain in engineered protein-based research reagents, and biologic clinical diagnostics and therapeutics, by eliminating the need for two separate polypeptide chain constructs, each encoding an NKG2D monomer, to generate a full NKG2D homodimer binding domain. The NKG2Dscd form of NKG2D decoys can also have affinity for ligands improved by joining protomers together which may then be mutated symmetrically or asymmetrically.
Particular embodiments can utilize at least two NKG2D monomers provided above to form a NKG2Dscd. An exemplary human NKG2Dscd includes: NQEVQIPLTESYCGPCP KNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPT NGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTVQIPLTESYCG PCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHMGLV HIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV (SEQ ID NO: 3).
An exemplary murine NKG2Dscd includes: NKEVPVSSREGYCGPC PNNWICHRNNCYQFFNEEKTWNQSQASCLSQNSSLLKIYSKEEQDFLKLVKSYHWMGLVQIPA NGSWQWEDGSSLSYNQLTLVEIPKGSCAVYGSSFKAYTEDCANLNTYICMKRAVPVSSREGY CGPCPNNWICHRNNCYQFFNEEKTWNQSQASCLSQNSSLLKIYSKEEQDFLKLVKSYHWMGL VQIPANGSWQWEDGSSLSYNQLTLVEIPKGSCAVYGSSFKAYTEDCANLNTYICMKRAV (SEQ ID NO: 4).
Multimerization. Particular embodiments include a multimeric form of the NKG2D decoy. The NKG2D decoy include NKG2D monomers multimerized by linear concatenation, by ferritin-based multimerization, by coiled-coil multimerization, etc. For example, particular embodiments can utilize an exemplary human bivalent NKG2Dscd linear concatemer:
Particular embodiments can utilize an exemplary murine bivalent NKG2Dscd linear concatemer: NKEVPVSSREGYCGPCPNNWICHRNNCYQFFNEEKTWNQSQASCLSQNSSLLKI YSKEEQDFLKLVKSYHWWMGLVQIPANGSWQWEDGSSLSYNQLTLVEIPKGSCAVYGSSFKAY TEDCANLNTYICMKRAVPVSSREGYCGPCPNNWICHRNNCYQFFNEEKTWNQSQASCLSQN SSLLKIYSKEEQDFLKLVKSYHWMGLVQIPANGSWQWEDGSSLSYNQLTLVEIPKGSCAVYGS SFKAYTEDCANLNTYICMKRAVNKEVPVSSREGYCGPCPNNWICHRNNCYQFFNEEKTWNQS QASCLSQNSSLLKIYSKEEQDFLKLVKSYHWMGLVQIPANGSWQWEDGSSLSYNQLTLVEIPK GSCAVYGSSFKAYTEDCANLNTYICMKRAVPVSSREGYCGPCPNNWICHRNNCYQFFNEEKT WNQSQASCLSQNSSLLKIYSKEEQDFLKLVKSYHWMGLVQIPANGSWQWEDGSSLSYNQLTL VEIPKGSCAVYGSSFKAYTEDCANLNTYICMKRAV (SEQ ID NO: 6).
As indicated, linear concatemers include repeating functional units.
In particular embodiments, C4b multimerization domains are used. C4 binding protein (C4b) is the major inhibitor of the classical complement and lectin pathway. The complement system is a major part of innate immunity and is the first line of defense against invading microorganisms. Orchestrated by more than 60 proteins, its major task is to discriminate between host cells and pathogens and to initiate immune responses when necessary. It also recognizes necrotic or apoptotic cells. Hofmeyer et al., J. Mol. Biol. 2013 Apr. 26; 425(8):1302-17.
Full-length native C4b includes seven α-chains linked together by a multimerization (i.e., heptamerization) domain at the C-terminus of the α-chains. Blom et al., (2004) Mol. Immunol. 40: 1333-1346. One of the α-chains can be replaced by a β-chain in humans. The wild-type C4b multimerization domain is 57 amino acid residues in humans and 54 amino acid residues in mice. Forbes et al., PLoS One. 2012; 7(9): e44943. It contains an amphipathic α-helix region, which is necessary and sufficient for heptamerization, as well as two cysteine residues which stabilize the structure. Kask et al., (2002) Biochemistry 41: 9349-9357.
The sequences of a number of C4b domain proteins are available in the art. These include human C4b multimerization domains as well as a number of homologues of human C4b multimerization domain available in the art. There are two types of homologues: orthologues and paralogues. Orthologues are defined as homologous genes in different organisms, i.e. the genes share a common ancestor coincident with the speciation event that generated them. Paralogues are defined as homologous genes in the same organism derived from a gene, chromosome or genome duplication, i.e. the common ancestor of the genes occurred since the last speciation event.
GenBank indicates mammalian C4b multimerization domain homologues in species including chimpanzees, rhesus monkeys, rabbits, rats, dogs, horses, mice, guinea pigs, pigs, chicken, and cattle. Further C4b multimerization domains may be identified by searching databases of DNA or protein sequences, using commonly available search programs such as BLAST.
Particular C4b multimerization domains that can be used include:
In particular embodiments, the C4b multimerization domain will be a multimerization domain which includes (i) G at position 12, (ii) A at position 28, (iii) L at positions 29, 34, 36, and/or 41; (iv) Y at position 32; (v) K at position 33; and/or (vi) C at positions 6 and 18. In particular embodiments, the C4b multimerization domain will be a multimerization domain which includes (i) G at position 12, (ii) A at position 28, (iii) L at positions 29, 34, 36, and 41; (iv) Y at position 32; (v) K at position 33; and (vi) C at positions 6 and 18.
C4b multimerization domains can include any of SEQ ID NOs. 7-39 with an N-terminal deletion of at least 1 consecutive amino acid residues (eg. at least 2, 3, 4, 5, 6, 7, 8, 9, 10 consecutive amino acid residues) in length. Additional embodiments can include a C-terminal deletion of at least 1 consecutive amino acid residues (eg. at least 2, 3, 4, 5, 6, 7, 8, 9, 10 consecutive amino acid residues) in length.
Particular C4b multimerization domain embodiments will retain or will be modified to include at least 1 of the following residues: A6; E11; A13; D21; C22; P25; A27; E28; L29; R30; T31; L32; L33; E34; 135; K37; L38; L40; E41; 142; Q43; K44; L45; E48; L49; or Q50. Further embodiments will retain or will be modified to include A6; E11; A13; D21; C22; P25; A27; E28; L29; R30; T31; L32; L33; E34; 135; K37; L38; L40; E41; 142; Q43; K44; L45; E48; L49; and Q50. Particular C4b multimerization domain embodiments will include the amino acid sequence “AELR”. For additional information regarding C4b multimerization, see WO/91/11461.
Particular embodiments can utilize an exemplary multimerization domain linked to an exemplary human NKG2Dscd. For example, particular embodiments include the multimerization domain: (SEQ ID NO: 7) linked to the human NKG2D: (SEQ ID NO: 1 or 76) or the murine NKG2D (SEQ ID NO: 2) Particular embodiments include the multimerization domain: (SEQ ID NO: 7) linked to the human NKG2Dscd: (SEQ ID NO: 3) or linked to SEQ ID NO: 5. Particular embodiments include the multimerization domain: (SEQ ID NO: 7) linked to the murine NKG2Dscd: (SEQ ID NO: 4) or linked to SEQ ID NO: 6. SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 and/or 39 can also be linked to SEQ ID NO: 1, 2, 3, 4, 5, 6, or 76.
As will be understood by one of ordinary skill in the art, all sequences disclosed herein and all combinations of resulting NKG2D decoys can additionally include additional amino acid sequences to include further beneficial attributes. For example, sequences disclosed herein can include tag peptides which in particular embodiments can provide an epitope to which an anti-tag antibody can selectively bind. The epitope tag generally can be placed at the amino- or carboxyl-terminus of the NKG2D decoy. However, in particular embodiments, an epitope tag can be placed within the amino acid sequence of a NKG2D decoy. In particular embodiments, an epitope tag can be used as a linker to join a NKG2D domain to a second NKG2D domain and/or to a multimerization domain or another peptide or another type of molecule. In particular embodiments a linker can be GSSGSSG (SEQ ID NO: 40). The presence of such epitope-tagged forms of NKG2D decoys can be detected using an antibody against the epitope tag. Also, provision of the epitope tag enables the NKG2D decoy to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag; this also can be useful for binding the NKG2D decoy to a support for heterogeneous screening methods. Various tag polypeptides and their respective antibodies are well known in the art. Examples include a flag tag (e.g., DYKDE (SEQ ID NO: 41); poly-histidine tags (e.g., HHHHHH (SEQ ID NO: 42)) or poly-histidine-glycine tags (e.g., GSHHHHHH (SEQ ID NO: 43); GTKHHHHHH (SEQ ID NO: 44)); the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering, 3(6):547-553 (1990)). Other tag polypeptides include the KT3 epitope peptide (Martin et al., Science, 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)).
In particular embodiments, the NKG2D decoy includes an intervening linker between an NKG2D monomer, a second NKG2D monomer and/or a multimerization domain (e.g., C4b multimerization domain). In general, the amino acids within the linker sequences are not deleterious to the biological function (e.g., NKG2DL binding affinity) of the NKG2D decoy, and may even be beneficial to biological function. Alternatively, a NKG2D decoy can lack linker sequences, but for the linker sequence between NKG2D monomers. Particular embodiments can include flexible linkers described elsewhere herein and/or Gly-Ser linkers (e.g., GGS). In particular embodiments, rigid linker sequences, such as proline-rich sequences may also be used.
NKG2D decoys may additionally include additional domains such as additional antigen or antigenic fragment (e.g., 2, 3, 4, 6, 8, 10 additional antigens or antigenic fragments).
“Variants” include protein sequences having one or more amino acid additions, deletions, stop positions, or substitutions, as compared to a protein sequence disclosed elsewhere herein.
An amino acid substitution can be a conservative or a non-conservative substitution. Variants of protein sequence disclosed herein can include those having one or more conservative amino acid substitutions. A “conservative substitution” or “conservative amino acid substitution” involves a substitution found in one of the following conservative substitutions groups: Group 1: A, G, S, T; Group 2: D, E; Group 3: N, Q; Group 4: R, K, H; Group 5: I, L, M, V; and Group 6: F, Y, W.
Additionally, amino acids can be grouped into conservative substitution groups by similar function, chemical structure, or composition (e.g., acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, an aliphatic grouping may include, for purposes of substitution, G, A, V, L, and I. Other groups including amino acids that are considered conservative substitutions for one another include: sulfur-containing: M and C; acidic: D, E, N, and Q; small aliphatic, nonpolar or slightly polar residues: A, S, T, P, and G; polar, negatively charged residues and their amides: D, N, E, and Q; polar, positively charged residues: H, R, and K; large aliphatic, nonpolar residues: M, L, I, V, and C; and large aromatic residues: F, Y, and W.
Non-conservative substitutions include those that significantly affect: the structure of the peptide backbone in the area of the alteration (e.g., the alpha-helical or beta-sheet structure); the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. Non-conservative substitutions which in general are expected to produce the greatest changes in the protein's properties are those in which (i) a hydrophilic residue (e.g. S or T) can be substituted for (or by) a hydrophobic residue (e.g. L, I, F, V, or A); (ii) a C or P can be substituted for (or by) any other residue; (iii) a residue having an electropositive side chain (e.g. K, R, or H) can be substituted for (or by) an electronegative residue (e.g. Q or D); or (iv) a residue having a bulky side chain (e.g. F), can be substituted for (or by) one not having a bulky side chain, (e.g. G). Additional information is found in Creighton (1984) Proteins, W.H. Freeman and Company.
Variants of protein sequences disclosed herein also include proteins with at least 70% sequence identity, at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity to a protein sequence disclosed herein.
Variants of proteins disclosed herein include proteins that share: 70% sequence identity with any of SEQ ID NO: 1-79; 75% sequence identity with any of SEQ ID NO: 1-79; 80% sequence identity with any of SEQ ID NO: 1-79; 81% sequence identity with any of SEQ ID NO: 1-79; 82% sequence identity with any of 1-79; 83% sequence identity with any of SEQ ID NO: 1-79; 84% sequence identity with any of SEQ ID NO: 1-79; 85% sequence identity with any of SEQ ID NO: 1-79; 86% sequence identity with any of SEQ ID NO: 1-79; 87% sequence identity with any of SEQ ID NO: 1-79; 88% sequence identity with any of SEQ ID NO: 1-79; 89% sequence identity with any of SEQ ID NO: 1-79; 90% sequence identity with any of SEQ ID NO: 1-79; 91% sequence identity with any of SEQ ID NO: 1-79; 92% sequence identity with any of SEQ ID NO: 1-79; 93% sequence identity with any of SEQ ID NO: 1-79; 94% sequence identity with any of SEQ ID NO: 1-79; 95% sequence identity with any of SEQ ID NO: 1-79; 96% sequence identity with any of SEQ ID NO: 1-79; 97% sequence identity with any of SEQ ID NO: 1-79; 98% sequence identity with any of SEQ ID NO: 1-79; or 99% sequence identity with any of SEQ ID NO: 1-79.
“Percent (%) amino acid sequence identity” with respect to the sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence for each of the NKG2D monomer(s), the multimerization domain (e.g., C4b), a non-NKG2D fusion partner, etc., and/or the complete fusion after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared. For example, % amino acid sequence identity values generated using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology, 266:460-480 (1996)) uses several search parameters, most of which are set to the default values. Those that are not set to default values (i.e., the adjustable parameters) are set with the following values: overlap span=1, overlap fraction=0.125, word threshold (T)=11 and scoring matrix BLOSUM62.
Variants will typically exhibit the same qualitative biological activity and elicit a substantially similar biological response as a reference peptide, although variants can be selected to modify the characteristics of a reference peptide as needed. Screening of variants can be performed using assays of NK cell activities, as known in the art. In particular embodiments, there is no statistically-significant difference in a biological effect in an in vitro NK cell activation assay between a variant peptide and a reference peptide.
Covalent modifications of NKG2D decoys are included within the scope of the disclosure. One type of covalent modification includes reacting targeted amino acid residues of NKG2D decoys with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of NKG2D decoys. Derivatization with bifunctional agents can be useful, for instance, for crosslinking NKG2D decoys to a water-insoluble support matrix or surface for use in the methods described below, or for in vivo stability. Commonly used crosslinking agents include 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters (e.g., esters with 4-azidosalicylic acid), homobifunctional imidoesters, including disuccinimidyl esters (e.g., 3,3′-dithiobis(succinimidylpropionate), bifunctional maleimides (e.g., bis-N-maleimido-1,8-octane) and agents such as methyl-3-((p-azidophenyl)dithio) propioimidate, and 1-ethyl-3-(-3-dimethylaminopropyl)carbodiimide hydrochloride.
Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of P and L, phosphorylation of hydroxyl groups of S or T residues, methylation of the amino groups of L, R, and H side chains (see, e.g., T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, and/or amidation of any C-terminal carboxyl group. In addition, modifications such as derivitization with polyethylene glycols (and other glycols) to increase the in vivo stability half-life are also included.
Glycosylation. In particular embodiments, the NKG2D decoys are glycosylated. Glycosylation is a type of post-translational modification that refers to the covalent attachment of sugars to proteins. Functions of glycosylation include contributing to proper protein folding, and facilitating cell-to-cell and/or protein-protein interactions.
Sugars that can be linked to proteins through glycosylation include glycans and monosaccharides, such glucose and fucose. Glycans are polysaccharides with sugar subunits linked by glycosidic bonds. Sugars that can be present in glycans include mannose, sialic acid, GlcNAc, galactose, and fucose. Glycans are a diverse class of molecules and can vary in the type of sugar moieties present, in the length of the chains of sugars, and in structure (branched or unbranched sugar chains). There are three major classes of glycans involved in protein glycosylation; N-linked glycans, O-linked glycans, and phospho-linked glycans.
In particular embodiments, the NKG2D decoys are N-linked glycosylated. N-linked glycans attach to the nitrogen atom of certain amino acids including N and R. In eukaryotic cells, N-linked glycosylation occurs during translation in the endoplasmic reticulum. Therefore, proteins that encode a signal peptide that signals for translation within the endoplasmic reticulum can become N-linked glycosylated. An N-linked glycosylation site can include N-X-(S), where X is any amino acid.
In particular embodiments, the human NKG2D monomer has three N-linked glycosylation sites (all N×S sequences), meaning a NKG2Dscd with two monomers has six. Crystallography performed on embodiments disclosed herein confirms that all potential N-linked oligosaccharide sites can be glycosylated.
In particular embodiments, the NKG2D decoys are O-linked glycosylated. O-linked glycans attach to the hydroxyl (OH) of amino acids including S, T, Y, hydroxyl-K, and hydroxyl-P. In eukaryotic cells, O-linked glycosylation occurs in the Golgi apparatus. An O-linked glycosylation site can include (S or T)-X-X-P, where X is any amino acid.
In particular embodiments, the NKG2D decoy is glycosylated due to protein production using a eukaryotic cell expression system. All domains of life (eukaryote, bacteria, and archaea) are capable of protein glycosylation. However, glycosylation machinery can differ across domains and even across species. Therefore, a protein that is glycosylated when expressed in an autologous system may not become glycosylated upon expression in a heterologous system. One specific reason is if the glycosylation site of the protein is not recognized by the cell type used for expression.
Particular embodiments disclosed herein may become glycosylated due to expression methods used. For example, in particular embodiments, NKG2D decoys disclosed herein are formed using the Daedalus expression system as described in Pechman et al., Am J Physiol 294: R1234-R1239, 2008. The Daedalus system utilizes inclusion of minimized ubiquitous chromatin opening elements in transduction vectors to reduce or prevent genomic silencing and to help maintain the stability of decigram levels of expression. This system can bypass tedious and time-consuming steps of other protein production methods by employing the secretion pathway of serum-free adapted human suspension cell lines, such as 293 Freestyle. Using optimized lentiviral vectors, yields of 20-100 mg/l of correctly folded and post-translationally modified, endotoxin-free protein of up to 70 kDa in size, can be achieved in conventional, small-scale (100 ml) culture. At these yields, most proteins can be purified using a single size-exclusion chromatography step, immediately appropriate for use in structural, biophysical or therapeutic applications. Bandaranayake et al., Nucleic Acids Res., 2011 (November); 39(21). In some instances, purification by chromatography may not be needed due to the purity of manufacture according the methods described herein.
Siderocalin (Scn), also known as Lipocalin-2 or neutrophil gelatinase-associated lipocalin, is a member of the lipocalin family that binds siderophores, a type of small chelator, with very high affinity (in the sub-nanomolar range). Scn also has an exceptionally stable protein structure, and therefore is an ideal binding partner for fusion proteins, as the stability of the Scn domain can impart stability on the whole fusion protein. Additionally, Scn naturally contains a secretion signal, so Scn can be a useful fusion partner for of a variety of peptides, proteins, and protein domains, including when extracellular expression is desired. Further, Scn possesses a single N-linked glycosylation site, which is involved in correct processing in the ER before secretion.
In particular embodiments, Scn particularly refers to the first isoform of the human ortholog of Scn (SWISS-PROT Data Bank Accession Number P80188. SEQ ID NO: 45 represents P80188 with the first 20 amino acids deleted. Other isoforms of human Scn may also be used (for example, SEQ ID NO: 77). In particular embodiments, Scn can refer to the ortholog expressed by another species, such as the mouse ortholog (SEQ ID NO: 46, which is SWISS-PROT Data Bank Accession Number P11672 with the first 20 amino acids deleted), or the rat ortholog (SEQ ID NO: 47, which is SWISS-PROT Data Bank Accession Number P30152 with the first 20 amino acids deleted). For additional orthologs, see
In particular embodiments, an exemplary expression construct includes: a signal peptide//a flag tag//a his tag//a linker//a siderocalin//a TEV protease site//NKG2D monomer 1//and NKG2D monomer 2. For example, such a sequence could include:
the signal peptide: METDTLLLWVLLLWVPGSTG (SEQ ID NO: 63) or TDTLLLWVLLLWVPGSTG (SEQ ID NO: 68);
the flag tag: (SEQ ID NO: 41); DYDE (SEQ ID NO: 69); or DYKDDDDK (SEQ ID NO: 74);
the his tag: (SEQ ID NO: 42);
the linker: GGS or SGGGS (SEQ ID NO: 70);
the siderocalin: (SEQ ID NO: 45) or (SEQ ID NO: 77);
the TEV protease site: ENLYFQK (SEQ ID NO: 64);
the NKG2D monomer 1: (SEQ ID NO: 1 or an extracellular fragment thereof); (SEQ ID NO: 76 or an extracellular fragment thereof); (SEQ ID NO: 65); (SEQ ID NO: 66); or (SEQ ID NO: 79); and the NKG2D monomer 2: (SEQ ID NO: 1 or an extracellular fragment thereof); (SEQ ID NO: 76 or an extracellular fragment thereof); (SEQ ID NO: 65); (SEQ ID NO: 66); or (SEQ ID NO: 79).
Together this exemplary sequence with selected options can provide:
In particular embodiments, an exemplary expression construct can include:
the signal peptide: (SEQ ID NO: 63) or (SEQ ID NO: 68);
the flag tag: (SEQ ID NO: 41); (SEQ ID NO: 69); or (SEQ ID NO: 74);
the his tag: (SEQ ID NO: 42);
the linker: GGS or (SEQ ID NO: 70);
the siderocalin: (SEQ ID NO: 45) or (SEQ ID NO: 77);
TEV protease site: (SEQ ID NO: 64);
the linker: GGS or (SEQ ID NO: 70);
the NKG2D monomer 1: (SEQ ID NO: 2 or an extracellular fragment thereof); (SEQ ID NO: 71);
or (SEQ ID NO: 72);
and the NKG2D monomer 2: (SEQ ID NO: 2 or an extracellular fragment thereof); (SEQ ID NO: 71); or (SEQ ID NO: 72).
Together this exemplary sequence with selected options can provide:
Any and all of these sequences can also incorporate a multimerization domain, such as a C4b multimerization domain selected from SEQ ID NOs. 7-39. For example, SEQ ID NO: 78 of
Compositions. Generally, NKG2D decoys can be formulated into pharmaceutically useful compositions, whereby therapeutically effective amounts of NKG2D decoys are combined in admixture with a pharmaceutically acceptable carrier. Salts and/or pro-drugs of NKG2D decoys can also be used.
A pharmaceutically acceptable salt includes any salt that retains the activity of the NKG2D decoys and is acceptable for pharmaceutical use. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
Suitable pharmaceutically acceptable acid addition salts can be prepared from an inorganic acid or an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids can be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids.
Suitable pharmaceutically acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, procaine, and the amino acids K or R.
A prodrug includes an active ingredient which is converted to a therapeutically active compound after administration, such as by cleavage of a NKG2D decoy or by hydrolysis of a biologically labile group.
In particular embodiments, the compositions include NKG2D decoys of at least 0.1% w/v or w/w of the composition; at least 1% w/v or w/w of composition; at least 10% w/v or w/w of composition; at least 20% w/v or w/w of composition; at least 30% w/v or w/w of composition; at least 40% w/v or w/w of composition; at least 50% w/v or w/w of composition; at least 60% w/v or w/w of composition; at least 70% w/v or w/w of composition; at least 80% w/v or w/w of composition; at least 90% w/v or w/w of composition; at least 95% w/v or w/w of composition; or at least 99% w/v or w/w of composition.
Exemplary generally used pharmaceutically acceptable carriers include any and all absorption delaying agents, antioxidants, binders, buffering agents, bulking agents or fillers, chelating agents, coatings, disintegration agents, dispersion media, gels, isotonic agents, lubricants, preservatives, salts, solvents or co-solvents, stabilizers, surfactants, and/or delivery vehicles.
Exemplary antioxidants include ascorbic acid, methionine, and vitamin E.
Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and/or trimethylamine salts.
An exemplary chelating agent is EDTA.
Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.
Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol.
Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the NKG2D decoys or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can include polyhydric sugar alcohols; amino acids, such as R, K, G, Q, N, H, A, ornithine, L-leucine, 2-phenylalanine, E, and T; organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol, and cyclitols, such as inositol; PEG; amino acid polymers; sulfur-containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, alpha-monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose; disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose, and polysaccharides such as dextran. Stabilizers are typically present in the range of from 0.1 to 10,000 parts by weight based on NKG2D decoy weight.
The compositions disclosed herein can be formulated for administration by, for example, injection, inhalation, infusion, insertion, perfusion, lavage, or ingestion. The compositions disclosed herein can further be formulated for intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral and/or subcutaneous administration and more particularly by intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, intrathecal, intratumoral, intramuscular, intravesicular, and/or subcutaneous ingestion, injection, or insertion.
For injection, compositions can be formulated as aqueous solutions, such as in buffers including Hanks' solution, Ringer's solution, or physiological saline. The aqueous solutions can contain formulatory agents such as suspending, stabilizing, and/or dispersing agents. Alternatively, the formulation can be in lyophilized and/or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
For oral administration, the compositions can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For oral solid formulations such as powders, capsules and tablets, suitable excipients include binders (gum tragacanth, acacia, cornstarch, gelatin), fillers such as sugars, e.g. lactose, sucrose, mannitol and sorbitol; dicalcium phosphate, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxy-methylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents can be added, such as corn starch, potato starch, alginic acid, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, solid dosage forms can be sugar-coated or enteric-coated using standard techniques. Flavoring agents, such as caramel, peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. can also be used.
Compositions can be formulated as an aerosol. In particular embodiments, the aerosol is provided as part of an anhydrous, liquid or dry powder inhaler. Aerosol sprays from pressurized packs or nebulizers can also be used with a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, a dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator may also be formulated containing a powder mix (including flavored mixes) of NKG2D decoys and a suitable powder base such as lactose or starch.
Compositions can also be formulated as suppositories and/or depot preparations. Depot preparations can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salts.
Additionally, compositions can be formulated as sustained-release systems utilizing semipermeable matrices of solid polymers containing at least one NKG2D decoy. Various sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release systems may, depending on their chemical nature, release NKG2D decoys following administration for a few weeks up to over 100 days. Depot preparations can be administered by injection; parenteral injection; instillation; or implantation into soft tissues, a body cavity, or occasionally into a blood vessel with injection through fine needles.
Depot formulations can include a variety of bioerodible polymers including poly(lactide), poly(glycolide), poly(caprolactone) and poly(lactide)-co(glycolide) (PLG) of desirable lactide:glycolide ratios, average molecular weights, polydispersities, and terminal group chemistries. Blending different polymer types in different ratios using various grades can result in characteristics that borrow from each of the contributing polymers.
The use of different solvents (for example, dichloromethane, chloroform, ethyl acetate, triacetin, N-methyl pyrrolidone, tetrahydrofuran, phenol, or combinations thereof) can alter microparticle size and structure in order to modulate release characteristics. Other useful solvents include water, ethanol, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), acetone, methanol, isopropyl alcohol (IPA), ethyl benzoate, and benzyl benzoate.
Exemplary release modifiers can include surfactants, detergents, internal phase viscosity enhancers, complexing agents, surface active molecules, co-solvents, chelators, stabilizers, derivatives of cellulose, (hydroxypropyl)methyl cellulose (HPMC), HPMC acetate, cellulose acetate, pluronics (e.g., F68/F127), polysorbates, Span® (Croda Americas, Wilmington, Del.), poly(vinyl alcohol) (PVA), Brij® (Croda Americas, Wilmington, Del.), sucrose acetate isobutyrate (SAIB), salts, and buffers.
Excipients that partition into the external phase boundary of microparticles such as surfactants including polysorbates, dioctylsulfosuccinates, poloxamers, PVA, can also alter properties including particle stability and erosion rates, hydration and channel structure, interfacial transport, and kinetics in a favorable manner.
Additional processing of the disclosed sustained release depot formulations can utilize stabilizing excipients including mannitol, sucrose, trehalose, and glycine with other components such as polysorbates, PVAs, and dioctylsulfosuccinates in buffers such as Tris, citrate, or histidine. A freeze-dry cycle can also be used to produce very low moisture powders that reconstitute to similar size and performance characteristics of the original suspension.
Any composition disclosed herein can advantageously include any other pharmaceutically acceptable carriers which include those that do not produce significantly adverse, allergic, or other untoward reactions that outweigh the benefit of administration. Exemplary pharmaceutically acceptable carriers and formulations are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. Moreover, formulations can be prepared to meet sterility, pyrogenicity, general safety, and purity standards as required by U.S. FDA Office of Biological Standards and/or other relevant foreign regulatory agencies. Any combination of formulation parameters can also be used so long as the combination does not detract from the appropriateness of the administration form (e.g., a flavored suppository).
Kits. Also disclosed herein are kits including one or more containers including one or more of the NKG2D decoys (e.g. in NKG2Dscd, pre-multimerized, or multimerized form) and/or compositions described herein. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use, or sale for human administration.
Optionally, the kits described herein further include instructions for using the kit in the methods disclosed herein. In various embodiments, the kit may include instructions regarding preparation of the NKG2D decoys, multimerization of the decoys, and/or compositions for administration; administration of the NKG2D decoys and/or compositions; appropriate reference levels to interpret results associated with using the kit; proper disposal of the related waste; and the like. The instructions can be in the form of printed instructions provided within the kit or the instructions can be printed on a portion of the kit itself. Instructions may be in the form of a sheet, pamphlet, brochure, CD-Rom, or computer-readable device, or can provide directions to instructions at a remote location, such as a website. In various embodiments, possible side effects and contraindications to further use of components of the kit based on a subject's symptoms can be included.
Methods of Use. Particular embodiments utilize NKG2D decoys to (i) identify NKG2DL; (ii) treat cancer, graft vs. host disease (GVHD), and inflammatory conditions; and (iii) potentiate an immune response against a vaccine as well as many other potential uses. NKG2D decoys bind to NKG2DL with high affinity and/or avidity and block or substantially reduce native NKG2D activation with little to virtually no risk of activation through native NKG2D binding.
Methods disclosed herein include treating subjects (humans, veterinary animals (dogs, cats, reptiles, birds, etc.) livestock (horses, cattle, goats, pigs, chickens, etc.) and research animals (monkeys, rats, mice, fish, etc.) with NKG2D decoys disclosed herein including pharmaceutically-acceptable salts, tautomers, isomers and prodrugs thereof and/or pharmaceutical compositions including the NKG2D decoys including pharmaceutically-acceptable salts, tautomers, isomers and prodrugs thereof. Treating subjects includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and/or therapeutic treatments. Therapeutically effective amounts need not produce a full desired outcome (e.g., potentiation of vaccine response), treatment or cure for a condition but can also provide a partial outcome or treatment such as alleviation or improvement of at least one cause or symptom of the condition.
An “effective amount” is the amount of a composition necessary to result in a desired physiological change in the subject. Effective amounts are often administered for research purposes. Effective amounts disclosed herein can cause a statistically-significant effect in an animal model or in vitro assay relevant to the assessment of a condition.
A “prophylactic treatment” includes a treatment administered to a subject who does not display signs or symptoms of a condition or displays only early signs or symptoms of the condition such that treatment is administered for the purpose of diminishing, preventing, or decreasing the risk of developing the condition further. Thus, a prophylactic treatment functions as a preventative treatment against a condition. In particular embodiments, prophylactic treatments include vaccines and/or can prevent, reduce, or delay the development or return of a condition.
A “therapeutic treatment” includes a treatment administered to a subject who displays symptoms or signs of a condition and is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of the condition. The therapeutic treatment can reduce, control, or eliminate the presence or activity of the condition (or its underlying causes) and/or reduce control or eliminate side effects of the condition.
Function as an effective amount, prophylactic treatment or therapeutic treatment are not mutually exclusive, and in particular embodiments, administered dosages may accomplish more than one treatment type.
Identification of NKG2DL. In particular embodiments, NKG2D decoys can be administered to a subject to locate cells or areas of the subject's anatomy bearing NKG2DL. In these embodiments, NKG2D decoys are associated with a detectable label. Following administration, the NKG2D decoys will bind to NKG2DL within the subject, permitting detection of these cells or areas within the subject through the detectable label.
Detectable labels can be detected following administration to a subject using imaging techniques. Examples of imaging techniques include magnetic resonance imaging (MRI), magnetic resonance tomography (MRT), positron emission tomography (PET), computer tomography (CT), single-photon emission computed tomography (SPECT) and optical imaging, such as x-ray.
Detectable labels can include any suitable label or detectable group detectable by, for example, optical, spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Such detectable labels include radiolabels (e.g., 35S, 125I, 32P, 3H, 14O, 131I), radioacoustic labels, enzyme labels (e.g., horseradish peroxidase, hydrolases, alkaline phosphatase), chemiluminescence labels, fluorescence labels (e.g., rhodamine, phycoerythrin, fluorescein, fluorescent proteins, Texas red), fluorescent proteins (e.g. a green fluorescent protein or one of its many modified forms), gold beads, magnetic beads (e.g. Dynabeads™), and biotin (with labeled avidin or streptavidin).
NKG2D decoys also can be utilized to identify and/or characterize NKG2DL in ex vivo and/or in vitro research settings.
Methods to Treat Cancer. Cancer (neoplasia) is characterized by deregulated cell growth and cell division. It has the potential to invade to other parts of the body. In 2015, there is an estimated 1.7 million new cases of cancer and 590,000 cancer deaths in the U.S. There are various types of cancer, including acoustic neuroma, adenocarcinoma, astrocytoma, basal cell cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, bronchogenic cancer, central nervous system cancer, cervical cancer, chondrosarcoma, choriocarcinoma, colon cancer, craniopharyogioma, ependymoma, Ewing's tumor, fibrosarcoma, glandular cancer, glioma, hemangioblastoma, hepatocellular carcinoma, hepatoma, kidney cancer, leiomyosarcoma, liver cancer, liposarcoma, lung cancer, melanoma, medulloblastoma, medullary cancer, medullary thyroid cancer, menangioma, mesothelioma, myxosarcoma, neuroblastoma, oligodendroglioma, osteogenic sarcoma, ovarian cancer, papillary adenocarcinomas, papillary thyroid cancer, pancreatic cancer, pheochromocytomas papillary cancer, pineal cancer, prostate cancer, renal cell cancer, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland cancer, seminoma, skin cancer, squamous cell cancer, sweat gland cancer, synovioma, testicular cancer, and/or Wilms' tumor. Cancers also include blood or other liquid cancers (e.g., lymphoma; leukemia).
Effective amounts disclosed herein can cause a statistically-significant effect in an animal model or an in vitro assay relevant to the assessment of a NKG2D decoy as an anti-cancer therapeutic.
In particular embodiments, a “prophylactic treatment” prevents, reduces, or delays metastasis from a primary tumor site and/or prevents, reduces, or delays a cancer recurrence.
Within a subject, a “therapeutic treatment” can decrease the number of cancer cells, decrease the number of metastases, decrease tumor volume, induce apoptosis of cancer cells, induce cancer cell death, induce chemo- or radio-sensitivity in cancer cells, inhibit angiogenesis near cancer cells, inhibit cancer cell proliferation, and/or inhibit tumor growth. Therapeutic treatments can also increase life expectancy, prolong a subject's life, reduce cancer-associated pain, and/or reduce relapse or re-occurrence of the cancer following treatment. In particular embodiments therapeutically effective amounts prevent, reduce, or delay the number or severity of metastatic tumors.
In particular embodiments, a statistically-significant change in a desired direction (e.g., reduction or increase) of one of these parameters is required to determine that a dose provides a therapeutically effective amount.
Additional support for the use of NKG2D decoys in the treatment of cancer comes from Example 2 and Spear et al., Cancer Immunity, (1 May 2013) Vol. 13, page 8.
In particular embodiments, treating cancers includes treating NKG2D+ cancers such as ovarian cancer and blood cancers, such as acute myeloid leukemia. In particular embodiments, treating NKG2D+ cancer includes reducing soluble MICA or MICB binding to NKG2D. In particular embodiments, treating NKG2D+ cancer includes measuring soluble MICA or MICB in a subject with NKG2D+ cancer.
Methods to Treat Graft vs. Host Disease (GVHD). GVHD is a generic name for diseases that are caused by the immune reaction of transferred or transplanted immunocompetent cells (graft; e.g., mature T cells) against host (recipient subject) tissues and that can induce severe organ toxicity leading to death in some cases. GVHD can occur despite aggressive immunosuppressive prophylaxis even when the donor is a perfectly matched (HLA identical) sibling. It is a consequence of interactions between antigen presenting cells of recipients and mature-cells of a donor.
GVHD can be divided into acute and chronic forms: the acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality; the chronic form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival.
NKG2D activation plays an important role in GVHD. Thus, administration of NKG2D decoys can provide prophylactic and/or therapeutic treatments against GVHD.
Efficacy of GVHD effective amounts can be assessed using animal models. For example, immunodeficient NOD.SCIDyc−/− (NSG) mice (e.g., from the Jackson Laboratory) can be irradiated at 2 Gy before injection of 2106 total Peripheral Blood Mononuclear cells (PBMC) from healthy donors. Weight loss and survival of injected mice overtime can be assessed as clinical parameters of GVHD appearance and severity. Weight loss can be represented as the percentage of initial weight of the injected mice at different time points after PBMC injection. Blood and spleen cells can also be harvested and frequencies of T cells can be determined by flow cytometry using human-specific fluorescent mAbs.
GVHD can also be manifested (and hence therapeutically effective amounts providing prophylactic and/or therapeutic treatments identified) based on presence and/or severity of intestinal inflammation, sloughing of the mucosal membrane, diarrhea, abdominal pain, nausea, and vomiting. GVHD can be diagnosed via intestinal biopsy. Liver GVHD can be measured by bilirubin level. Skin GVHD results in a diffuse maculopapular rash, sometimes in a lacy pattern. Kidney function can be assessed by measuring creatinine and/or BUN levels. Therapeutically effective amounts disclosed herein can reduce these symptoms and/or preserve organ function in a statistically-significant manner.
Acute GVHD can be staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of 1 to a high of 4. Patients with grade IV GVHD usually have a poor prognosis. Therapeutically effective amounts disclosed herein can reduce GVHD scores or prevent occurrence of a grade IV score.
Additional support for the use of NKG2D decoys as an effective treatment against GVHD comes from Karimi et al., Blood, prepublished on-line Mar. 18, 2015 doi:10.1182/blood-2015-02-629006 (NKG2D Expression by CD8+ T-Cells Contributes to GVHD and GVT Effects in a Murine Model of Allogeneic HSCT).
Methods to Treat Inflammatory Conditions. Inflammatory conditions refer to any disorder or disease characterized or caused by excessive or uncontrolled inflammation, or any aspect of inflammation such as redness, swelling, heat, and pain. Examples of inflammatory conditions include allergies (e.g., allergic rhinitis/sinusitis, skin allergies (e.g., urticaria/hives, angioedema, atopic dermatitis), food allergies, drug allergies, insect allergies, and rare allergic disorders such as mastocytosisasthma), asthma, arthritis (e.g., osteoarthritis, rheumatoid arthritis, and spondyloarthropathies), gastrointestinal inflammation, neuroinflammatory disorders, and autoimmune disorders.
Autoimmune disorders include any condition, or disease in which the immune system mounts a reaction against self cells or tissues, due to a breakdown in the ability to distinguish self from non-self or otherwise. Examples of autoimmune disorders include Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, polymyositis, Guillain Barre, Wegener's granulomatosus, polyarteritis nodosa, polymyalgia rheumatica, temporal arteritis, Bechet's disease, Churg-Strauss syndrome, Takayasu's arteritis, and others. Autoimmune disorders can involve any component of the immune system, and can target any cell or tissue type in the body.
U.S. Pat. No. 9,127,064 provides a method of treating inflammatory conditions including autoimmune disorders. More particularly, U.S. Pat. No. 9,127,064 describes a method of treating rheumatoid arthritis, inflammatory bowel disease (IBD) (including Crohn's disease and ulcerative colitis), systemic erythromatosis lupus (SLE), psoriasis, psoriatic arthritis, multiple sclerosis, celiac disease, viral disease (such as, e.g., viral hepatitis), and transplant rejection of various organs and tissues (including heart and bone marrow). These inflammatory conditions are treated by reducing or inhibiting hNKG2D activation, hNK2D-signalling, or activation of hNKG2D-expressing NK or T cells using human or humanized anti-hNKG2D antibodies. The NKG2D decoys disclosed herein are preferable treatments because of the significantly reduced risk of NKG2D binding and activation.
Therapeutically effective amounts providing effective amounts, prophylactic treatments and/or therapeutic treatments can be identified by selecting a relevant animal or clinical model of the particular inflammatory disease at issue and identifying a statistically-significant effect or improvement.
Additional support for the use of NKG2D decoys disclosed herein in the effectiveness against autoimmune disorders such as rheumatoid arthritis, celiac disease and diabetes is provided by Steigerwald et al., mAbs, 1:2, 115-127 (March/April 2009).
Methods to Potentiate Immune Responses against a Vaccine. Vaccines increase the immunity of a subject against a particular condition, such as infection by a virus (e.g., HIV, HCV). Therefore, in particular embodiments, a vaccine may be administered prophylactically, for example to a subject that is immunologically naive (e.g., no prior exposure or experience with a condition or limited prior exposure or experience with a condition).
Vaccine efficacy is often significantly decreased in the elderly and in developing countries including vaccines with very well-established efficacy in the U.S. and Europe such as the measles, polio and rotavirus vaccines (e.g., 90% efficacy in Europe vs. 32% in South Africa for the GSK RV1 rotavirus vaccine). While the causes for the efficacy decrease are certainly multi-factorial, a common denominator in these cases is the increased frequency of memory T cells highlighting their great potential as therapeutic target.
In the vaccine context, and not limiting the term as described elsewhere herein, subjects can include those in need of treatment, such as, those with an infection, as well as those prone to have or develop an infection, or those in whom infection is to be prevented, such as those in a high risk group for exposure to a pathogen, such as a virus. For example, NKG2D decoys can be administered to subjects who are at risk of developing a viral infection, or who have been exposed to a pathogen (e.g., virus), to prevent, reduce, or delay the development of infection or disease. In particular embodiments, NKG2D decoys can be administered to a subject likely to have been exposed to a pathogen or to a subject who is at high risk for exposure to a pathogen.
In particular embodiments, a vaccine is a therapeutically effective amount of an antigen in combination with an NKG2D decoy disclosed herein that induce an immune response in a subject against the antigen. The skilled artisan will appreciate that the immune system generally is capable of producing an innate immune response and an adaptive immune response. An innate immune response generally can be characterized as not being substantially antigen specific and/or not generating immune memory. An adaptive immune response can be characterized as being substantially antigen specific, maturing over time (e.g., increasing affinity and/or avidity for antigen), and in general can produce immunologic memory. Even though these and other functional distinctions between innate and adaptive immunity can be discerned, the skilled artisan will appreciate that the innate and adaptive immune systems can be integrated and therefore can act in concert.
“Immune response” refers to a response of the immune system to a vaccine antigen. In various exemplary embodiments, an immune response to a vaccine antigen can be an innate and/or adaptive response. In particular embodiments, an adaptive immune response can be a “primary immune response” which refers to an immune response occurring on the first exposure of a “naive” subject to a vaccine antigen. For example, in the case of a primary antibody response, after a lag or latent period of from 3 to 14 days depending on, for example, the composition, dose, and subject, antibodies to the vaccine antigen can be produced. Generally, IgM production lasts for several days followed by IgG production and the IgM response can decrease. Antibody production can terminate after several weeks but memory cells can be produced. In particular embodiments, an adaptive immune response can be a “secondary immune response”, “anamnestic response,” or “booster response” which refer to the immune response occurring on a second and subsequent exposure of a subject to a vaccine antigen. Generally, in a secondary immune response, memory cells respond to the vaccine antigen and therefore the secondary immune response can differ from a primary immune response qualitatively and/or quantitatively. For example, in comparison to a primary antibody response, the lag period of a secondary antibody response can be shorter, the peak antibody titer can be higher, higher affinity antibody can be produced, and/or antibody can persist for a greater period of time.
Thus, in particular embodiments, an immune response against a vaccine antigen will include antibody production against the vaccine antigen.
“Antibodies” refer to polyclonal or monoclonal antibodies that can be induced by vaccine antigen and later protect against its associated pathogen. In particular embodiments, an antibody prevents and/or ameliorates a symptom of a condition caused by a pathogen (e.g, AIDS caused by HIV infection). Thus, in particular embodiments, an antibody can bind to a pathogen based on exposure to the associated vaccine antigen. Without being bound by theory, in particular embodiments, the binding of an antibody to a pathogen can substantially neutralize or inactivate the pathogen. Thus, antibodies are capable of reducing or eliminating a pathologic effect of a pathogen. In particular embodiments, the binding of antibodies to pathogens may decrease or eliminate pathogen infectivity and/or virulence factor activity, including replication, synthesis, and/or toxicity. In particular embodiments, a statistically-significant decrease of one of these parameters upon re-exposure to a pathogen is required to determine that a NKG2D decoy potentiated an immune response against a vaccine, or, in other words, provided a therapeutically effective amount. In particular embodiments, a statistically-significant decrease in lag time to antibody upregulation following re-exposure to a pathogen is required to determine that a NKG2D decoy potentiated an immune response against a vaccine. In particular embodiments, potentiation of an immune response against a vaccine can be demonstrated by a statistically-significant increase in a vaccine parameter following its initial administration (e.g., higher peak antibody titers, higher affinity antibody production, antibody persistence).
For administration, therapeutically effective amounts (also referred to herein as doses) for all uses described herein can be initially estimated based on results from in vitro assays and/or animal model studies. Such information can be used to more accurately determine useful doses in subjects of interest.
The actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of condition, type of condition, stage of condition, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.
Useful doses can range from 0.1 to 5 μg/kg or from 0.5 to 1 μg/kg. In other non-limiting examples, a dose can include 1 μg/kg, 5 μg/kg, 10 μg/kg, 15 μg/kg, 20 μg/kg, 25 μg/kg, 30 μg/kg, 35 μg/kg, 40 μg/kg, 45 μg/kg, 50 μg/kg, 55 μg/kg, 60 μg/kg, 65 μg/kg, 70 μg/kg, 75 μg/kg, 80 μg/kg, 85 μg/kg, 90 μg/kg, 95 μg/kg, 100 μg/kg, 150 μg/kg, 200 μg/kg, 250 μg/kg, 350 μg/kg, 400 μg/kg, 450 μg/kg, 500 μg/kg, 550 μg/kg, 600 μg/kg, 650 μg/kg, 700 μg/kg, 750 μg/kg, 800 μg/kg, 850 μg/kg, 900 μg/kg, 950 μg/kg, 1000 μg/kg, 0.1 to 5 mg/kg or from 0.5 to 1 mg/kg. In other non-limiting examples, a dose can include 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 55 mg/kg, 60 mg/kg, 65 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 85 mg/kg, 90 mg/kg, 95 mg/kg, 100 mg/kg, 150 mg/kg, 200 mg/kg, 250 mg/kg, 350 mg/kg, 400 mg/kg, 450 mg/kg, 500 mg/kg, 550 mg/kg, 600 mg/kg, 650 mg/kg, 700 mg/kg, 750 mg/kg, 800 mg/kg, 850 mg/kg, 900 mg/kg, 950 mg/kg, 1000 mg/kg or more.
Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or yearly)
The pharmaceutical compositions described herein can be administered by, without limitation, injection, inhalation, infusion, insertion, perfusion, lavage or ingestion. Routes of administration can include intravenous, intradermal, intraarterial, intraparenteral, intranasal, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral, subcutaneous, and/or sublingual administration and more particularly by intravenous, intradermal, intraarterial, intraparenteral, intranasal, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intratumoral, intramuscular, intravesicular, oral, subcutaneous, and/or sublingual ingestion, injection, or insertion.
NKG2D Decoy Manufacturing Protocols. Expression constructs were engineered as C-terminus fusions to a human Lipocalin protein Siderocalin (hScn) with N-terminus polyhistidine and short FLAG (SEQ ID NO: 74) affinity tags to facilitate protein expression analysis and purification. A Tobacco Etch Virus (TEV) protease cleavage site (SEQ ID NO: 64) was designed between C-terminus of hScn and N-terminus expression constructs.
Human Embryonic Kidney (HEK) suspension adapted freestyle 293F cells (Invitrogen) were used for protein expression. HEK 293F cells were stably transduced using expression lentivirus using previously outlined protocols (Bandaranayake, et al., supra; and Finton, et al. (2014) Ontogeny of recognition specificity and functionality for the broadly neutralizing anti-HIV antibody 4E10. PLoS Pathogens 10(9):e1004403). Stable lentiviral-based transductions were performed as follow, in brief, plasmids containing appropriate constructs were incorporated into replication incompetent lentiviral particles. HEK-293F cells plated in fresh media at one million per mL in 10 mL of fresh freestyle media were transduced with pseudovirus particles. Cells were incubated at 37° C. with 8% CO2 and 80% humidity. 8-16 hours post transduction; cells were supplemented with 25 mL of fresh freestyle media. Transduction efficiency and protein expression were verified qualitatively by assessing GFP/mCherry expression using EVOS fluorescence imaging systems (Life Technologies). Three days post transduction; cells were expanded at a cell density of 0.5 million per mL.
Large-scale expression and purifications were performed in HEK 293F cells. Supernatant clarification and protein purification were done as described previously (Bandaranayake A D, et al., supra) with minor modification. Briefly, supernatants were harvested by centrifugation at 8000 rpm to remove cells and clarified by passing through 0.22-micron filter (Thermo Scientific). Clarified supernatants were supplemented with 150 mM Sodium Chloride. Affinity tagged protein purification was done using Ni-NTA. Recombinant proteins were further purified by size exclusion chromatography (SEC) using a Superdex 75 or Superdex 200 column (GE Healthcare) running in phosphate-buffered saline (PBS) running buffers. Eluted fractions were analyzed using SDS-PAGE. Protein concentrations were determined using calculated protein extinction coefficients and absorbance at 280 nm as a surrogate measure. Purified recombinant protein is further treated with TEV protease to separate fusion partners and generate soluble protein. Cleaved recombinant protein is further purified using affinity tag purification and SEC based gel filtration.
Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells. Introduction. The NKG2D lymphocyte receptor enables tumor immune surveillance by stimulating cytotoxic natural killer (NK) cells and CD8 T cells upon engagement of ligands that are induced on cancer cells by malignant transformation (Ullrich et al., Oncoimmunology 2013; 2(10):e26097). However, progressing tumors in humans stifle immune responses by various tactics that include chronic stimulation and functional disabling of lymphocyte NKG2D (Groh et al., Nature 2002; 419(6908):734-8, Groh et al., Nat Immunol 2006; 7(7):755-62, Hanaoka et al., J Immunol 2010; 185(10):5732-42). In a conceptual twist, this detrimental activity is escalated as some cancer cells (such as subsets of breast, colon, ovarian, and prostate cancer cells) co-opt expression of NKG2D, thereby complementing the presence of its ligands for autonomous stimulation of oncogenic signaling (Benitez et al., Proc Natl Acad Sci USA 2011; 108(10):4081-6). In lymphocytes and cancer cells alike, stable NKG2D expression and function depend on its association with the DAP10 (DNAX-activating protein 10) signaling adaptor, which initiates PI3K-AKT and MAPK (mitogen-activated protein kinase) signaling cascades (Benitez et al., supra, Upshaw et al., Semin Immunol 2006; 18(3):167-75). In cancer cells, these pathways control various aspects of tumorigenesis (Vivanco et al., Nat Rev Cancer 2002; 2(7):489-501, Normanno et al., Gene 2006; 366(1):2-16). NKG2D ligands (NKG2DL) include MICA and MICB (MHC class I-related chains A and B) and six members of the ULBP (UL-16 binding protein) family (Eagle & Trowsdale, Nat Rev Immunol 2007; 7(9):737-44). NKG2DL are typically absent from the surface of most normal cells but are induced by oncogenesis-associated cellular stress and other disease conditions (Groh et al., Proc Natl Acad Sci USA 1996; 93(22):12445-50, Raulet et al., Annu Rev Immunol 2013; 31:413-41). NKG2DL are abundant in essentially all types of cancers but display variability in the representation of different ligand types (Groh et al., Proc Natl Acad Sci USA 1999; 96(12):6879-84, McGilvray et al., Int J Cancer 2010; 127(6):1412-20).
In diverse cancer settings, the continuous presence of NKG2DL correlates with poor clinical outcomes (McGilvray et al., Int J Cancer 2010; 127(6):1412-20, Wu et al., J Clin Invest 2004; 114(4):560-8, Cancer Immunol Immunother 2009; 58(5):641-52, Duan et al., Med Oncol 2011; 28(2):466-74, Fang et al., J Exp Clin Cancer Res 2014; 33:76). One plausible explanation considers the role of NKG2DL in promoting tumor immune evasion (Groh et al., Nature 2002; 419(6908):734-8, Groh et al., Nat Immunol 2006; 7(7):755-62, Hanaoka et al., J Immunol 2010; 185(10):5732-42). An alternative scenario that is not mutually exclusive and tentatively supported by preliminary clinical data, is based on oncogenic effects of cancer cell NKG2D lending selective advantage to NKG2DL expression (Benitez et al., supra). NKG2D signaling may have the capacity to promote cancer cell plasticity and stemness-reprogramming, cellular changes that are considered central to tumor dissemination and metastasis formation (Scheel & Weinberg, Semin Cancer Biol 2012; 22(5-6):396-403). This notion is supported by phenotypic profiling of model tumor lines and ex vivo isolated breast cancer cells (Cai et al., PLoS One 2014; 9(10):e108942). As of yet, however, functional evidence that cancer cell NKG2D may indeed impart bona fide stem-like attributes is missing. This report aims at closing this knowledge gap. Building on a clinical correlation study of ovarian cancer, in vitro experiments and mouse model xenograft assays are presented, providing evidence that links NKG2D signaling to induction of cancer stem cell attributes and tumor initiation.
Materials and Methods. Ex vivo and xenograft ovarian cancer specimens, cell suspensions, and cell lines. Primary epithelial ovarian cancer (EOC) surgical specimens and annotated histopathology, International Federation of Gynecologists and Obstetricians (FIGO) tumor stage, and patient follow-up information were obtained from the Cooperative Human Tissue Network (www.chtn.nci.nih.gov) and the Pacific Ovarian Cancer Research Consortium Specimen Repository under Fred Hutchinson Institutional Review Board protocol #6007/552. Xenograft-derived tumors were harvested in accordance with Fred Hutchinson Institutional Animal Care and Use Committee (IACUC) protocol #1870. Processing of tumor specimens to single cell suspensions used a Human Tumor Tissue Dissociation Kit and a gentleMACS™ Dissociator (both Miltenyi Biotech; Cai et al., PLoS One 2014; 9(10):e108942). Single-cell processing of tumor spheres was in phosphate buffered saline (PBS) with 2 mM EDTA. The MDAH-2774 tumor line (American Type Culture Collection; ATCC) was grown in RPMI-1640/10% fetal bovine serum. The cytotoxic NKL cell line was grown in RPMI-1640/10% human serum/Interleukin 2 (100 IU; Chiron; Robertson et al., Exp Hematol 1996; 24(3):406-15).
Transfectants and siRNA transduction. MDAH-2774-derived NKG2D-DAP10 transfectants (MDAH-2774-TF cells) have been described (Cai et al., PLoS One 2014; 9(10):e108942). Additional transfectants with vector control (MDAH-2774 mock cells), and NKG2D RNAi-transduced MDAH-2774-TF-KO cells or scrambled RNAi controls (MDAH-2774-TF-scrRNAi cells) were generated as described (Benitez et al., supra). C1R-MICA, C1R-MICB, EL4-ULBP1, EL4-ULBP2, EL4-ULBP3, Mel-ULBP4, EL4-ULBP5, and C1R-ULBP6 transfectants have been described (Groh et al., Nat Immunol 2006; 7(7):755-62, Eagle et al., Eur J Immunol 2009; 39(11):3207-16). Silencing of NKG2D in ex vivo ovarian cancer cells was as with the MDAH-2774-TF line.
Engineering a biologic inhibitor of NKG2D signaling. “Single-chain dimer” forms of NKG2D (NKG2Dscd) were designed using a segment of the N-terminal arm of NKG2D as a linker between domains within the native homodimer. NKG2Dscd targeting units were multimerized through fusion with the minimal heptamerization motif from human C4b binding protein (C4bbp) (Hofmeyer et al., J Mol Biol 2013; 425(8):1302-17), yielding highly-avid NKG2Dscd heptamers (NKG2Dscd7). Both NKG2Dscd and NKG2Dscd7 proteins were expressed using the Daedalus platform in HEK293F cells (Invitrogen) as fusions with Siderocalin (Scn) to stabilize expression (Bandaranayake et al., supra, Finton et al., PLoS Pathog 2013; 9(9):e1003639). A Tobacco Etch Virus protease (TEV) scission site (EDLYFQ; (SEQ ID NO: 75)) was inserted between the Scn and NKG2D moieties, and N-terminal polyhistidine and FLAG (SEQ ID NO: 74) tags were incorporated to facilitate purification. Recombinant proteins were purified from culture supernatants by immobilized metal chelate affinity, treated with TEV protease to release the Scn fusion partner, and polished by size exclusion chromatography (SEC). Purity and proper folding were confirmed by comparative reduced/non-reduced SDS-PAGE and analytical SEC. Endotoxin levels were checked using the PyroGene rFc assay (Lonza), and NKG2Dscd7 was labeled with fluorescein isothiocyanate (Sigma-Aldrich) at a ratio of two fluorophores per protomer. Surface plasmon resonance (SPR) interaction analyses confirming that NKG2Dscd and NKG2Dscd7 retain proper binding to NKG2DL were performed at 25° C. with Biacore T100 instrumentation on a Series S CM5 chip (GE Healthcare). NKG2Dscd and NKG2Dscd7 proteins were immobilized using standard amine coupling chemistry, yielding surfaces with 310 or 240 SPR response units (RUs), respectively. A reference surface was generated by activating and deactivating a flow cell in the absence of protein. Serial two-fold dilutions of soluble, wild-type MICA (240 nM to 0.47 nM, or 100 nM to 0.78 nM), produced as previously described (Kim et al., Adv Protein Chem Struct Biol 2008; 75:85-105), were prepared in a running buffer of HBS-EP+ (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% surfactant P-20; GE Healthcare) with 0.1 mg/mL bovine serum albumin. Duplicate MICA samples, interspersed with multiple buffer blanks, were randomly injected at 50 μL/min, with 3 min of association and 5 min of dissociation. Surfaces were regenerated with a 10 sec injection of 10 mM glycine, pH 2.0, followed by 2 min of buffer stabilization. Double-referenced data were fit with a 1:1 binding model using BIAevaluation 2.0.4 software (GE Healthcare).
Sphere formation assay. Tumor cells were cultured at 5×103, 1×104, and 5×104 cells/ml when using ex vivo cancer cells, or 1×103 cells/ml when using tumor lines, in 96-well ultra low attachment plates in mammary epithelial cell growth (MEBM) medium (Lonza) with 0.9% methylcellulose (Sigma Aldrich) (Kwong et al., J Mol Biol 2008; 384(5):1143-56). After 3-4 weeks, >100 μm diameter tumor spheres were microscopically counted in triplicate wells. For serial passaging, primary spheres were dissociated to single cells and replated in MEBM. Cultures were monitored for secondary and tertiary sphere formation for up to four weeks. To block NKG2D-NKG2DL engagement, assays were in the presence of either a cocktail of antibodies (Abs) specific for MICA/B (6D4; BD Pharmingen) and ULBP1-6 [clones 170818 (ULBP1), 165903 (ULBP2,5,6), and 166510 (ULBP3) from R&D Systems; and clone 1H11 (ULBP4; 3)], each at 10 μg/ml, or control isotype immunoglobulin (Ig), or the pan-NKG2DL-binding NKG2Dscd7 (10 μg/ml) or PBS control. Agonist anti-NKG2D Ab (clone 149810) was from R&D Systems (Kwong et al., J Mol Biol 2008; 384(5):1143-56).
Animal studies. All animal procedures were approved by Fred Hutchinson IACUC protocol #1870. Female non-obese diabetic/severe combined immunodeficient (NOD/SCID) and NOD scid gamma (NSG) mice (6-8 weeks old) were obtained from the Fred Hutchinson Core Center of Excellence in Hematology (DK-56465 and DK-106829) and housed under pathogen-free conditions at the institutional Comparative Medicine Shared Resource. For implants, mice were anaesthetized with isoflurane and injected subcutaneously into dorsal flanks with either ex vivo isolated cancer cells, or MDAH-2774-derived lines, each in 100 μl growth medium (1:1 PBS/BD Matrigel™ Matrix; BD Bioscience). Tumor development was monitored three times per week until tumor nodules were palpable and then in daily intervals. At experimental endpoints or when a tumor parameter reached 1.5 cm, animals were euthanized and tumors resected. For in vivo NKG2DL masking, mice were treated in weekly intervals (up to 4 weeks post-transplant) with either a cocktail of anti-MICA/B, anti-ULBP1, -ULBP3, -ULBP4, and -ULBP5 Abs (see above) or NKG2Dscd7 or relevant controls, all administered subcutaneously at the site of tumor cell implants or via tail vein injection. Antibody or NKG2Dscd7 dosages were 10 μg per local application or 100 μg per tail vein injection.
Flow cytometry. Ex vivo EOC- or xenograft tumor-derived cell suspensions or sphere-derived single cells (in PBS/10% human serum/0.15% sodium azide) were variably incubated with pretitrated Ab-fluorochrome conjugates to NKG2D (clone 1D11; APC), CD45 (clone 2D1; APC-H7), CD44 (clone G44-26; PerCP-Cy5.5) (all BD Pharmingen), and EpCAM (clone 9C4; Alexa Fluor 488; Biolegend). NKG2DL expression was examined using an Ab cocktail (see above). Anti-H2Dd (clone 34-2-12; Biolegend) was used for exclusion of murine cells. DAPI was used for live/dead cell distinction. Isotype Igs were used as controls and background fluorescence subtracted. Testing for tumor cell aldehyde dehydrogenase activity was with the ALDEFLUOR™ kit (Stemcell Technologies) according to the manufacturer's instructions. Briefly, tumor cells were incubated with ALDEFLUOR {boron, [N-(2,2-diethoxyethyl)-5[(3,5-dimethyl-2H-pyrrol-2-ylidene-kN)methyl]-1H-pyrrole-2-propanamida to KN1]difluoro-, (T-4)-(9Cl)} in the absence or presence of ALDH1 activity inhibitor diethylaminobenzaldehyde (DEAB) for 30 min at 37° C. followed by one wash using ALDEFLUOR assay buffer (Stemcell Technologies) and surface staining for NKG2D, CD45 and EpCAM. DEAB-treated cells served to set baseline ALDH1 activities. To confirm binding of NKG2Dscd7 to all NKG2DL, corresponding transfectants (see above) were incubated with FITC-conjugated NKG2Dscd7 (2 μg/ml) or PBS control for 30 min on ice followed by two PBS washes. Stained cells were analyzed using a BD LSRII flow cytometer (BD Biosciences) and FlowJo software (Tree Star). Cell sorting was on a FACSAria™ (BD Biosciences).
Cytotoxicity assay. CellTrace™ Violet (Life Technologies)-labeled C1R-MICA and Oregon GreenR 488 (ThermoFisher Scientific)-labeled C1R-mock target cells were mixed at equal numbers and exposed to NKL cells at 1:1 effector to target (E:T) ratios in the presence or absence of NKG2Dscd7 (10 μg/ml) or PBS control. Anti-MICA/B Ab 6D4 (10 μg/ml) served as positive blocking control. Following 4 h incubation at 37° C., E:T cell mixes were stained using LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Molecular Probes) and analyzed by flow cytometry. Ratios of live C1R-mock to C1R-MICA cells were used as measure of cytotoxic activity.
Statistical analyses. Frequencies of NKG2D+ cancer cells were divided into subgroups represented by NKG2D Low (≤median % NKG2D+ cells) and NKG2D High (>median % NKG2D+ cells). Logistic regression was used to assess the relationship of NKG2D subgroups with disease recurrence and tumor stage (I/II vs. III/IV). Models were adjusted for patient age and odds ratios (OR) from these models refer to the increase in odds of outcome (disease recurrence or high tumor stage) for the NKG2D High subgroup compared to NKG2D Low. P-values were derived from likelihood ratio statistics and are two-sided. Kaplan-Meier curves and the log-rank test were used to analyze progression-free survival rates between the subgroups. All analyses were performed using R version 3.3.1 (R Core team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2006 URL https://www.R-project.org/). Extreme Limiting Dilution Analysis (ELDA) was as described (Hu & Smyth, J Immunol Methods 2009; 347(1-2):70-8).
Results. Correlation between NKG2D positive cancer cells and negative disease outcomes in epithelial ovarian cancer. In a previous study of a mixed cohort of breast, ovarian, colon, and prostate cancers, positive correlations were recorded between the frequencies of cancer cells bearing NKG2D (NKG2D+ cancer cells) and tumor stage (Benitez et al., supra). This relationship could possibly reflect NKG2D effects on induction and/or maintenance of cancer stem-like traits. However, this interpretation is premature due to study limitations such as the inclusion of aggregate data from heterogeneous cancer cases and lack of disease outcome information. A follow-up study was therefore devised that focused on epithelial ovarian cancer (EOC) and addressed outcome. EOCs typically express abundant NKG2DL, which are strongly associated with negative disease outcomes (McGilvray et al., Int J Cancer 2010; 127(6):1412-20, Li et al., Cancer Immunol Immunother 2009; 58(5):641-52). Oncogenic effects of cancer cell NKG2D could thus be particularly apparent in this malignancy.
It was previously determined that cell surface flow cytometry of ex vivo isolated tumor cells is the method of choice for enumerating cancer cells expressing signaling competent NKG2D (Benitez et al., supra). A total of 47 primary EOC surgical specimens (procured between January 2009 and June 2015) were thus processed to cell suspensions and examined by flow cytometry for frequencies of cancer cells (defined as CD45-EpCAM+) positive for surface NKG2D. EpCAM is a bona fide cancer cell marker although expression levels can vary substantially (Munz et al., Cancer Res 2009; 69(14):5627-9). Hence, all non-hematopoietic (CD45-) cells with above threshold EpCAM staining were scored as cancer cells. All tumors represented high grade serous (HGS) carcinoma, the most prevalent histological subtype among EOC (Kurman et al., Am J Pathol 2016; 186(4):733-47). FIGO stage and disease outcome annotations are summarized in
Association of NKG2D with markers of cellular plasticity among ex vivo ovarian cancer cells. With breast cancer cells, expression of NKG2D preferentially segregates with marker profiles characteristic of the epithelial-mesenchymal transition and metastable capacities (Cai et al., PLoS One 2014; 9(10):e108942). To test whether similar relationships apply to HGS EOC, ex vivo isolated tumor cell suspensions were examined by multi-parameter flow cytometry for non-hematopoietic (CD45-) NKG2D and markers of high plasticity traits represented by EpCAM together with CD44, or high aldehyde dehydrogenase (ALDH1) enzymatic activity (Silva et al., Cancer Res 2011; 71(11):3991-4001, Strauss et al., PLoS One 2011; 6(1):e161864, Kuroda et al., PLoS One 2013; 8(6):e65158). In a first set of five tumor specimens (EOC1 through EOC5; see
In vitro evidence for functional stem cell-like capacities of NKG2D+ ovarian cancer cells. Stem cell-like cancer cells have the ability to form tumor spheres in cell culture (Dontu et al., Genes Dev 2003; 17(10):1253-70, Liao et al., PLoS One 2014; 9(1):e84941). CD45-NKG2D and control NKG2D− cancer cells from altogether eight ex vivo HGS EOC tumor cell suspensions were FACSAria sorted. Cells were cultured under classical adherence-independent sphere-formation conditions and monitored for the appearance of spheres over a three-week period. NKG2D+ cells from all tumors formed numerous large (>100 μm diameter) spheres, even when plated at low cell densities, whereas control NKG2D− cells generated spheres only when plated at high density and those that developed were rare and typically small (
In support of a causal involvement of NKG2D in sphere formation, the sphere-forming abilities of NKG2D+ cancer cells were significantly reduced when NKG2D was depleted by recombinant lentivirus-mediated RNAi targeting whereas control scrambled RNAi had no effect (
In vivo evidence for stem cell-like capacities of NKG2D+ ovarian cancer cells. Experimental proof of stem-cell like functions requires documentation of efficient tumor-initiating capacities upon xenografting in immunodeficient mice (Ponti et al., Cancer Res 2005; 65(13):5506-11). FACSAria-sorted CD45-NKG2D+ or control NKG2D− cells from two HGS EOC tumor cell suspensions were subcutaneously inoculated at dosages of 5×103 and 1×104 cells into flanks of NSG mice. Three out of seven 5×103 and six out of eight 1×104 NKG2D+ cell implants initiated tumors as early as six weeks post inoculation. In contrast, only one of eight 1×104 NKG2D− cell implants led to tumor formation 14 weeks post inoculation (
NKG2D signaling stimulates cancer stem cell-like tumor initiation. Direct involvement of NKG2D in tumor initiation was initially explored using experimental variants and controls of the MDAH-2774 ovarian tumor line which lacks endogenous NKG2D. Cells transfected with signaling competent NKG2D-DAP10 (MDAH-2774-TF) or vector control (MDAH-2774 mock), or transduced with NKG2D RNAi (MDAH-2774-TF-KO) or scrambled RNAi control (MDAH-2774-TF-scrRNAi) have been previously established or were newly made (Cai et al., PLoS One 2014; 9(10):e108942). MDAH-2774-TF cells recapitulated sphere-formation as recorded with ex vivo NKG2D+ ovarian cancer cells (
In limiting dilution xenograft assays, three of four implants of as few as 100 MDAH-2774-TF cells formed tumors. Saturating tumor take with untransfected or mock transfected MDAH-2774 cells required implants of 1×104 cells (
To reinforce significance of these cell line-based experiments, tumor initiation by ex vivo NKG2D+ ovarian cancer cells sorted from HGS EOC37 (see
Blockade of tumor initiation by pan ligand-reactive NKG2D-based multimer. Cancers express diverse combinations of NKG2DL with variability between tumors (Groh et al., Proc Natl Acad Sci USA 1999; 96(12):6879-84, Groh et al., Proc Natl Acad Sci USA 1999; 96(12):6879-84, Li et al., Cancer Immunol Immunother 2009; 58(5):641-52). Confirmation of NKG2DL involvement in NKG2D-driven tumor initiation thus required an all-inclusive ligand masking approach. With pan-reactive Abs unavailable, a soluble form of NKG2D suitable for global ligand binding (
Thereafter, NKG2Dscd7 was used for testing of an involvement of NKG2DL in tumor initiation by ex vivo NKG2D+ ovarian cancer cells. Administrations (either locally at cell inoculation sites or systemically) prevented or reduced tumor formation, thus formally linking NKG2DL engagement and NKG2D stimulation to the tumor-initiating capacity of NKG2D+ ovarian cancer cells (
Discussion Expression of cell surface receptors encoded within the human NK gene complex is typically restricted to cells of hematopoietic origin. An exception is NKG2D, which, in addition to its normal distribution on CD8 T cells and NK cells, is also found on variable proportions of cancer cells in diverse types of epithelial malignancies. Previous in vitro studies and correlative clinical observations have provided preliminary evidence for a role of cancer cell NKG2D in high plasticity reprogramming but its full oncogenic potential has remained unknown. It is now shown that NKG2D+ ovarian cancer cells have the capacity for self-renewing sphere formation and efficient tumor initiation upon implantation into immunodeficient mice. Without being bound by mechanism, formal evidence that ligand engagement and hence NKG2D stimulation underlie this functional capacity is provided. The described results further suggest that NKG2D-driven tumor initiation accounts for a significant portion of the overall tumor initiation potential of a given ovarian cancer. The cancer cell NKG2DL-NKG2D signaling axis may thus represent an important regulator of tumorigenesis and dissemination, offering an explanation for the negative clinical associations found between frequencies of NKG2D+ cancer cells or abundance of NKG2DL expression and disease outcome (see
Enhancement of Vaccine Response. The memory CD8 T cell compartment can be activated by inflammatory cues even in the absence of a T cell receptor signal. This process is referred to as bystander-activation of memory T cells and has been observed following different infections. The contribution of these cells to host immunity was poorly understood until it was recently reported that bystander-activated memory CD8 T cells play a crucial role in controlling early pathogen replication following infection. It was demonstrated that bystander-activated memory CD8 T cells express granzyme B and can directly kill target cells in a TCR-independent, innate-like fashion. In stark contrast to their beneficial effect for host immunity following infection, recent data provides strong evidence that these bystander-activated T cells decrease antigen availability following vaccination by eliminating antigen-presenting cells.
NKG2D as a key molecule in this process and NKG2D decoys disclosed herein can be used as an antagonist to enhance vaccine efficacy by inhibiting bystander-activated CD8 T cell function. Without being bound by theory, following vaccination, bystander-activated memory T cells eliminate dendritic cells that present antigen and thereby decrease antigen availability and diminish primary adaptive immune responses. By inhibiting this innate-like function of memory CD8 T cells, vaccine efficacy is enhanced by preserving antigen-presenting cells.
Data described herein shows that inhibiting NKG2D-NKG2DL interactions increases the number of antigen-presenting dendritic cells and the ensuing CD4 and CD8 T cell response. Considering the limited frequency of memory phenotype cells in 8 wk old, SPF-housed B6 mice compared to a human T cell compartment, a much greater effect of bystander-activation on subsequent immune responses is predicted. Data is presented demonstrating that primary human influenza-specific CD8 T cells become bystander-activated. Interestingly, some CMV (pp65)-specific T cells already almost uniformly express granzyme B, a feature they share with human Natural Killer (NK) cells (while mouse NK cells do not express granzyme B ex vivo).
Acquisition of innate-like effector function in the absence of cognate TCR signals. An experimental system with defined TCR specificity was first used to determine BA-CTL phenotype and function. Memory T cells were generated by transferring low numbers of congenically marked, naïve OT-I T cells into B6 mice. OT-I cells recognize the SIINFEKL (N4) epitope of chicken ovalbumin (OVA). Mice were infected with a recombinant strain of vesicular stomatitis virus (VSV-OVA) to prime OT-I T cells. 30 days after the VSV-OVA infection, mice were infected with wild-type Listeria monocytogenes (VVT-LM), which does not express any antigen with agonist properties for OT-I T cells (i.e., does not prime naïve OT-I T cells) to induce bystander-activation (
The respective roles of the TCR and cytokines in bystander-activation. It was considered whether generation of BA-CTLs could (a) be completely independent of TCR signals, (b) depend on a basal signal (TCR tickling) or (c) depend on stronger than basal signals, possibly provided by cross-reactivity of the activated T cell to available antigen at any point of the activation process (Dontu et al., Genes Dev 2003; 17(10):1253-70). BA-CTLs may not necessarily be a homogeneous population and could be composed of some cells that are purely inflammation-activated and others that have cross-reactivity and are activated by TCR signals. To address these possibilities the recently described Nur77-GFP reporter mice (Moran et al. J. Exp. Med. 2011; 208:1279-89), in which the GFP expression level in T cells is directly proportional to the strength of the TCR stimulus a T cell receives and, importantly, independent of inflammatory signals were used. This was specifically shown in the context of an LM infection. Most importantly, the Nur77-GFP system is sensitive enough that it reports even very weak TCR signals. To establish the baseline and maximum GFP signal, one group of mice remained untreated and another group received an injection of aCD3 antibody as a positive control for TCR signaling (
CD44hi NKG2D+ granzyme B+ CD8 T cells in the LM-OVA infected group displayed GFP expression levels higher than CD44lo CD8 T cells, but congruent with the expression levels of the overall CD44lo+hi CD8 control population (black vs. gray lines,
It was next examined whether exposure to IL-12, IL-15 and IL-18 could directly induce granzyme expression and affect NKG2D expression in naïve and memory phenotype OT-I T cells. Robust granzyme expression in the memory phenotype population (CD44high), but not naïve CD8 T cell population after 24 hours of incubation with IL-12/15/18 (data not shown and 11) was found. Recent work describes a key role for monocytes and DCs in mediating bystander activation of memory CD8 T cells (Soudja et al., Immunity 2012; 37:549-62). Importantly, all three of these cytokines are expressed early after an infection, which is at least to some extent due to availability of preformed mRNA.
Identifying the target cells. Bystander-activated cells were phenotyped for expression of receptors associated with NK cell activation. NK cells have been shown to have similarities with CD8 memory T cells in phenotype, function and gene expression patterns and expression of inhibitory and activating NK cell receptors has been reported on CD8 T cell populations. BA-CTLs expressed NKG2D (
Providing early protection—a crucial role for BA-CTLs. To provide evidence that this BA-CTL-mediated, innate-like killing could occur in vivo, it was asked whether blocking NKG2D on BA-CTLs affects the course of an LM infection. An NKG2D-blocking antibody (Ito et al., International Immunology 2008; 20:1343-9) was administered 2 days before and after infecting mice with LM. Mice were also injected with depleting αNK1.1 antibody (clone PK136)57 to eliminate skewing of the results by NK and NKT cells, which can express NKG2D as well (
These data show that—in the context of an infection—the primary response is unaffected (in size and function) by treatment with NKG2D blocking antibody and thus not responsible for the difference in bacterial clearance in the experimental groups. Since mice were NK and NKT cell depleted, the data strongly support the notion that BA-CTLs are a key mediator of NKG2D-dependent, early bacterial clearance. A potential effect of γ/δ T cells in LM clearance was also excluded using TCR δ−/− animals in follow-up experiments (data not shown).
Moving from a mechanistic mouse model system to examining bystander activation in different human CD8 T populations. Many important mechanistic aspects and consequences of bystander-activation can only be addressed in a well-defined experimental system such as the mouse model system. Several pieces of strong evidence argue that bystander-activation is not just a “mouse phenomenon”, but actually very similar to bystander-activation in human memory T cells. Following in vitro stimulation NKG2D-dependent, TCR-independent killing of NKG2DL expressing target cells has been demonstrated for human CD8 T cells with an effector memory phenotype in vitro, although its biological significance was not clear (Verneris et al., Blood 2004; 103:3065-72). Bystander-activation of memory CD8 T cells has been demonstrated to occur in humans following EBV infection. Influenza-specific CD8 T cells transiently express granzyme during the acute phase of a primary EBV infection in a cohort of college students (Odumade et al., J. Exp. Med. 2012; 209:471-8). The authors showed that this was not due to epitope cross-reactivity and influenza-specific CD8 T cells lost granzyme expression after the acute EBV infection phase. To examine if the same mechanisms induce bystander-activation in mouse and human memory T cells, the effect of incubating human PBMCs with IL-12/15/18 for 24 hours was tested. Similar to what has been observed with mouse CD8 T cells before, memory phenotype (CD45RO+) CD28+ CD8 T cells increase their cytotoxic potential (data not shown). The ability of influenza- and CMV-specific T cells to become bystander-activated (
Bystander-activated CD8 memory phenotype T cells (BA-CTLs) affect vaccine efficacy. Background and Performed Studies: Shortening the duration of antigen presentation reduces the magnitude of the CD8 T cell response. The relevance of the duration of TCR engagement in dictating the magnitude and function of the antigen-specific CD8 T cell response has been addressed (Prlic et al., J. Exp. Med. 2006; 203:2135-43). Antigen was delivered through peptide pulsed DCs carrying a transgene encoding the diphtheria toxin receptor (DTRtg DCs). The DTRtg DCs can be efficiently removed by administration of the toxin without passing on the antigen to host APCs (and without affecting inflammation provided by an ongoing VVT-LM infection). The ability to discontinue antigen presentation within a defined time period allowed demonstration that the early interactions are sufficient to instruct the T cell for functionality, but longer contact with DCs is needed for optimal long-term proliferation and survival. Thus, the magnitude of clonal expansion, but not the functionality of the effector cells, correlated directly with the duration of antigen exposure (as long as systemic inflammation is provided). Based on these data, BA-CTL mediated elimination of APC will shorten the duration of antigen presentation and affect the size of the primary CD8 T cell response when antigen is limited.
Blocking BA-CTLs increases the antigen-specific CD8 T cell response in the context of immunization. To test the hypothesis that inhibiting BA-CTLs increases antigen availability and thus the size of the primary CD8 T cell response, mice were infected with actA− LM-OVA. This strain is attenuated and cannot spread from cell to cell and thus provides a limited amount of antigen (compared to a VVT-LM infection).
One group of infected mice received PK136 antibody treatment and the other group of infected mice received injections of PK136 and blocking NKG2D antibody (clone HMG2D) on days −2, 0 (=day of infection) and day 2 (
The next layer of complexity—reducing inflammation and TCR signal strength. In addition to limiting the duration of antigen presentation, BA-CTL mediated elimination of APCs might also lower the amount of overall antigen availability and dampen inflammation. It is proposed that this does not only affect the magnitude of the antigen-specific T cell response, but also the breadth of the T cell response. Generating a broad memory T cell population through vaccination is beneficial to overcome pathogen epitope variability. A memory T cell pool becomes broad in TCR diversity by recruiting high and low affinity T cells. the respective roles of TCR signal strength and inflammatory signals in regulating breadth and size of the T cell response was previously addressed and it was found that that bim-mediated cell death affects the size of the effector pool through TCR signal strength- and inflammation-mediated signals, but is overcome when low affinity cells are primed in the context of a replicating pathogen. These recently published data are summarized in
Generation of an NKG2Dscd7 to block NKG2D-ligand interactions. To explore the therapeutic potential of inhibiting NKG2D-ligand interactions an antagonist that does not target NKG2D itself was generated to prevent delivering an activating or inhibitory signal via NKG2D. As the affinity of NKG2D for its ligands is moderate, NKG2D was linked to the human C4b-binding protein heptamerization motif to engineer an NKG2Dscd7 (
Based on described data, it is proposed that BA-CTL mediated elimination of APCs affects the quality of the cellular and humoral immune response (
As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.” The transition term “comprise” or “comprises” means includes, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of” excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of” limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment. A material effect would cause a statistically-significant reduction in a NKG2D decoy's ability to reduce NKG2DL binding to native NKG2D in an in vitro binding assay utilizing NK cells.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. When further clarity is required, the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11% of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value.
Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
Particular embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching.
In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and/or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the following examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from Webster's Dictionary, 3rd Edition or a dictionary known to those of ordinary skill in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Ed. Anthony Smith, Oxford University Press, Oxford, 2004).
This application is a U.S. National Phase Patent Application based on International Patent Application No. PCT/US2016/061368, which claims priority to U.S. Provisional Patent Application No. 62/253,590 filed Nov. 10, 2015, the entire contents each of which are incorporated by reference herein. A computer readable text file, entitled “DN1SQ6253.txt (Sequence Listing.txt)” created on or about Nov. 8, 2016, with a file size of 89.4 KB, contains the Sequence Listing for this application and is hereby incorporated by reference in its entirety.
This invention was made with government support under grant CA174470 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2016/061368 | 11/10/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2017/083545 | 5/18/2017 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20110311535 | Dranoff et al. | Dec 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 102020717 | Apr 2011 | CN |
| 104894151 | Sep 2015 | CN |
| WO1991011461 | Aug 1991 | WO |
| WO2003089616 | Oct 2003 | WO |
| WO2003089616 | Oct 2003 | WO |
| WO2005097160 | Oct 2005 | WO |
| WO2005097160 | Oct 2005 | WO |
| WO2010080124 | Jul 2010 | WO |
| WO2014093403 | Jun 2014 | WO |
| WO2014093403 | Jun 2014 | WO |
| Entry |
|---|
| Dietrich, et al., “Peptides as Drugs: From Screening to Application”, Current Pharmaceutical Biotechnology, vol. 14, No. 5, Bentham Science Publishers, 2013, pp. 1-12. |
| Li, et al., “Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA,” Nat. Immunol., vol. 2, No. 5, 2001, pp. 443-451. |
| McFarland and Strong, “Thermodynamic Analysis of Degenerate Recognition by the NKG2D Immunoreceptor,” Immunity, vol. 19, 2003, pp. 803-812. |
| McFarland, et al., “Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands,” Structure, vol. 11, No. 4, 2003, pp. 411-422. |
| Invitation to Pay Additional Fees dated Feb. 6, 2017 for International Application No. PCT/US2016/061368. |
| Search Report and Written Opinion dated Apr. 21, 2017 in International Application No. PCT/US2016/061368. |
| Strong and McFarland, “NKG2D and related immunoreceptors,” Adv. Protein Chem., vol. 68, 2004, pp. 281-312. |
| Bauer, et al., “Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA,” Science, vol. 285, No. 5428, 1999, pp. 727-729. |
| Blom, et al., “Complement inhibitor C4b-binding protein-friend or foe in the innate immune system,” Mol. Immunol., vol. 40, No. 18, 2004, pp. 1333-1346. |
| Cai, et al. “Autonomous Stimulation of Cancer Cell Plasticity by the Human NKG2D Lymphocyte Receptor Coexpressed with Its Ligands on Cancer Cells,” PLoS One, vol. 9, No. 10, 2014, 13 pages. |
| Dissen, et al., “An Autosomal Dominant Locus, Nka, Mapping to the Ly-49 Region of a Rat Natural Killer (NK) gene Complex, Controls NK Cell Lysis of Allogeneic Lymphocytes,” J. Exp. Med., vol. 183, 1996, pp. 2197-2207. |
| Dontu, et al., “In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells,” Genes Dev, vol. 17, No. 10, 2003, pp. 1253-1270. |
| Forbes, et al., “T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein,” PLoS One, vol. 7, No. 9, 2012, 12 pages. |
| Ho, et al., “Murine Nkg2d and Cd94 are clustered with in the natural killer complex and are expressed independently in natural killer cells,” PNAS, USA, vol. 95, 1998, pp. 6320-6325. |
| Hofmeyer, et al., “Arranged sevenfold: structural insights into the C-terminal oligomerization domain of human C4b-binding protein,” J. Mol. Biol., vol. 425, No. 8, 2013, pp. 1302-1317. |
| Ito, et al., “NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allrecognition pathway,” International Immunology, vol. 20, No. 10, 2008, pp. 1343-1349. |
| Karimi, et al., “NKG2d Expression by CD8+ T cells contribute to GVHD and GVT effects in murine model of allogenic HSCT,” Blood, vol. 125, No. 23, 2015, pp. 3655-3663. |
| Kask, et al. “Structural requirements for the intracellular subunit polymerization of the complement inhibitor C4b-biding protein,” Biochemistry, vol. 41, No. 30, 2002, pp. 9349-9357. |
| Kim, et al., “A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effect cells: Comparisons to a 4 h 51Cr-release assay,” J. Immunol. Methods, vol. 325, No. 1-2, 2007, pp. 51-66. |
| Kwong, et al., “Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agnostic activity,” J. Mol. Biol., vol. 384, No. 5, 2008, pp. 1143-1156. |
| Lengyel, et al., “Mutations designed to destabilize the receptor-bound conformation increase MICA-NKG2D association rate and affinity,” J. Biol. Chem., vol. 282, No. 42, 2007, pp. 30658-30666. |
| Nausch, et al, “NKG2D ligands in tumor immunity,” Oncogene, vol. 27, No. 45, 2008, pp. 5594-5958. |
| PCT Invitation to Pay Additional Fees dated Feb. 6, 2017 for International Application No. PCT/US2016/061368, 3 pages. |
| Spear, et al., “NKG2D ligands as therapeutic targets,” Cancer Immunity, vol. 13, 2013, 14 pages. |
| Search Report and Written Opinion dated Apr. 21, 2017 in International Patent Application No. PCT/US2016/061368, 16 pages. |
| Steigerwald, et al., “Human IgG1 antibodies antagonizing receptor NKG2D on natural killer cells,” mAbs, vol. 1, No. 2, 2009, pp. 115-127. |
| Verneris, et al., “Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells,” Blood, vol. 103, No. 8, 2004, pp. 3065-3072. |
| Wu, et al., “An activating immunoreceptor complex formed by NKG2D and DAP10,” Science, vol. 285, No. 5428, 1999 pp. 730-732. |
| Allred, et al., “Siderocalin-mediated recognition, sensitization, and cellular uptake of actinides,” PNAS, vol. 112, No. 33, 2015, pp. 10342-10347. |
| Cai, et al., “Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells,” Neoplasia, vol. 19, No. 6, 2017, pp. 471-482. |
| Extended European Search Report dated Apr. 24, 2019 in European Application No. 16865019.0, 10 pages. |
| Garrity, et al., “The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure,” PNAS, vol. 102, No. 21, 2005, pp. 7641-7646. |
| Ogun, et al., “The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria,” Infect. Immun., vol. 76, No. 8, 2008, pp. 3817-3823. |
| Stark, et al., “The use of trimeric isoleucine-zipper fusion proteins to study surface-receptor-ligand interactions in natural killer cells,” J. Immunol. Methods., vol. 296, No. 1-2, 2005, pp. 149-158. |
| Xia, et al., “Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice,” J. Immunother, vol. 37, No. 5, 2014, pp. 257-266. |
| Yan, et al., “Delivery of human NKG2D-IL-15 fusion gene by chitosan nanoparticles to enhance antitumor immunity,” Biochem. Biophys. Res. Commun., vol. 463, No. 3, 2015, pp. 336-343. |
| Number | Date | Country | |
|---|---|---|---|
| 20180371051 A1 | Dec 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62253590 | Nov 2015 | US |
